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ABSTRACT 
BACKGROUND: Periodontitis causes persistent inflammation, connective tissue 
breakdown and alveolar bone destruction, mediated by various types of Pro-
inflammatory mediators. One of such pro-inflammatory mediator is interleukin–6, 
which is a signalling protein/cytokine produced by several cells including 
macrophages, neutrophils, keratinocytes, and fibroblasts, in response to stimulus such 
as infection and trauma. Interleukin-6 and lipopolysaccharides from microorganisms 
stimulate the hepatic expression of an acute-phase protein called hepcidin, which 
inhibits duodenal absorption of iron. This in turn may lead to anaemia of chronic 
disease. In an anaemic state there is increased periodontal destruction because of 
relative decrease in oxygen perfusion into tissues. 
AIM:  The aim of this study is to determine and compare the level of serum hepcidin 
and interleukin-6 before and after phase-I periodontal therapy in patients with chronic 
and aggressive periodontitis.  
MATERIALS AND METHOD: In the present study, 45 subjects were selected, of 
which 15 were categorized as Group I which consisted of healthy subjects, 15 were 
categorized as Group II which consisted of patients with chronic periodontitis and 
another 15 were categorized as Group III which consisted of patients with aggressive 
periodontitis. The clinical parameters assessed were plaque index, gingival bleeding 
index, pocket probing depth, clinical attachment level. The laboratory parameters 
assessed were serum IL-6 and hepcidin level. All the parameters were assessed at 
baseline in group I, at baseline and 3 months after phase I therapy in group II and III.  
RESULTS: The levels of serum Hepcidin and IL-6 were elevated in chronic and 
aggressive periodontitis patients when compared with healthy subjects at baseline. 
However, there was no statistically significant difference in baseline values of Hepcidin 
and IL-6 between chronic and aggressive periodontitis patients. Following Phase I 
therapy there was a statistically significant reduction from baseline values in 
PI,GBI,PPD,CAL and serum levels of Hepcidin,IL-6 in chronic and aggressive 
periodontitis patients. 
CONCLUSION: Within the limitations of this study, it could be concluded that 
increased serum IL-6 and hepcidin level is associated with both chronic and aggressive 
periodontitis patients which increases the risk for the development of anemia of chronic 
disease. However, there was no statistically significant difference in baseline values of 
Hepcidin and IL-6 between chronic and aggressive periodontitis patients. Following 
phase I therapy the levels of both IL-6 and Hepcidin reduced in chronic and aggressive 
periodontitis patients. In future, studies with a larger sample size may be employed to 
further establish the association between serum Hepcidin levels and periodontal status 
of the patient and to evaluate the efficiency of phase I therapy in reducing serum IL-6 
and Hepcidin levels. This will help to reduce the systemic burden of the patient like 
development of anaemia, CVS complications etc., 
KEY WORDS: Hepcidin, Interleukin-6, Anaemia of chronic disease, chronic 
periodontitis, Aggressive periodontitis 
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INTRODUCTION 
Chronic periodontitis is an inflammatory disease of the supporting tissues of the teeth 
caused by specific microorganisms or groups of specific microorganisms, resulting in 
progressive destruction of the periodontal ligament and alveolar bone with pocket 
formation, recession or both (Carranza’s clinical periodontology 11th edition)1 
Aggressive periodontitis is the disease of the periodontium occurring in an otherwise 
healthy individual which is characterised by a rapid loss of alveolar bone about more 
than one tooth of the permanent dentition. The amount of destruction manifested is not 
in proportion with the amount of local irritants (Baer et al, 1971)  
Although the presence of periodontopathogens is needed for disease initiation in both 
conditions, it is inadequate for progression and increased severity of disease. The onset, 
progression, and severity of periodontal disease are related to the interaction between 
periodontal microorganisms and the host immune response2,3,4. In response to bacterial 
endotoxins and mediators that cause tissue breakdown, acute phase proteins, cytokines, 
and prostaglandins, are produced as part of the host response.5,6 
Acute-phase response occurs in the innate host response to injuries, infections, or 
ischemic necrosis by releasing various acute-phase proteins, such as C reactive protein 
and fibrinogen7,8. Data show that levels of various acute-phase proteins increased in 
periodontal disease in both gingival crevicular fluid (GCF) and plasma or serum.9 
Cytokines, which are soluble proteins, play an important role in the initiation and 
maintenance of inflammatory and immune responses.10 Interleukin-6 (IL-6), a 
multifunctional cytokine, is the major regulator of acute-phase protein synthesis during 
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acute-phase response and one of the most studied inflammatory markers in periodontal 
disease. 
IL-6 is promptly produced in an infected or a damaged lesion and provides an emergent 
signal to the entire body. When stimulating hepatocytes, IL-6 strongly induces a broad 
spectrum of acute-phase proteins such as C-reactive protein (CRP), serum amyloid A 
(SAA), fibrinogen, hepcidin, haptoglobin, and antichymotrypsin, whereas it reduces 
albumin, cytochrome p450, fibronectin, and transferrin11. 
Elevated levels of serum pro-inflammatory cytokines and inflammatory mediators, 
such as IL-6 and CRP, have been shown to be associated with measures of periodontal 
disease. Interleukin-6 and lipopolysaccharides from microorganisms stimulate the 
hepatic expression of the acute-phase protein hepcidin, which inhibits duodenal 
absorption of iron.  
Hepcidin is a cationic peptide that is rich in cysteine. It is synthesized by the liver and 
excreted by the kidney and its main function is homeostatic regulation of iron 
metabolism.12 The target for serum hepcidin is the iron exporter ferroportin-I13, which 
is found in the plasma membranes of most body cells and at high concentrations in 
duodenal enterocytes, macrophages and hepatocytes.  
Increased circulating hepcidin, due to inflammatory stimulation such as chronic 
periodontitis, induces internalization and degradation of ferroportin, whose loss from 
cell surface prevents the exit of iron from inside the cells into the plasma, resulting in 
low transferrin saturation which leads to the decrease of erythropoiesis, contributing to 
the development of anemia of chronic disease.  
The anemia of chronic disease refers to the impaired production of erythrocytes 
associated with chronic inflammatory states, including cancer, chronic infection, or 
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autoimmune diseases. Recent data indicate that anemia can also occur in the setting of 
severe, acute inflammation, such as critical illness, or with milder but persistent 
inflammatory signals that occur in obesity, aging, and kidney failure. For these reasons, 
the name “anemia of inflammation”(AI) may be more suitable than anemia of chronic 
disease.14 
In a study by Carvalho 2015, the serum Hepcidin and interleukin-6 levels were found 
to be higher in chronic periodontitis patients when compared with healthy subjects. 
Currently there are no studies regarding hepcidin levels in aggressive periodontitis 
patients. This study will help to estimate the hepcidin levels in aggressive periodontitis 
patients and compare it with hepcidin levels in chronic periodontitis patients and 
healthy individuals and to compare serum hepcidin and interleukin-6 levels before and 
after phase I periodontal therapy in patients with chronic and aggressive periodontitis. 
 
 
Aims and objectives 
 
4 
 
AIM AND OBJECTIVES 
AIM 
The aim of this study is to determine and compare the level of serum hepcidin and 
interleukin-6 before and after phase-I periodontal therapy in patients with chronic and 
aggressive periodontitis.  
OBJECTIVES 
 To measure serum hepcidin and interleukin-6 levels in healthy subjects.  
 To measure serum hepcidin and interleukin-6 levels in patients with chronic 
periodontitis.  
 To measure serum hepcidin and interleukin-6 levels in patients with aggressive 
periodontitis.  
 To compare serum hepcidin and interleukin-6 levels in individuals with healthy 
periodontium (control group) and chronic periodontitis(study group) and 
aggressive periodontitis(study group)  
 To measure and compare serum hepcidin and interleukin-6 levels before and 
after phase I periodontal therapy in patients with chronic periodontitis.  
 To measure and compare serum hepcidin and interleukin-6 levels before and 
after phase I periodontal therapy in patients with aggressive periodontitis.  
 To compare the serum IL-6 and hepcidin levels between chronic and aggressive 
periodontitis patients. 
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REVIEW OF LITERATURE 
Periodontal disease is an inflammatory disease initiated by microbial infections that 
lead to a host response, which results in inflammatory breakdown of tooth-supporting 
osseous and soft tissues. The presence of periodontopathogens alone is inadequate for 
progression and increased severity of disease. The onset, progression, and severity of 
periodontal disease are related to the interaction between periodontal microorganisms 
and the host immune response. 
In response to bacterial endotoxins, the host releases mediators that cause tissue 
breakdown. This includes acutephase proteins, cytokines, and prostaglandins etc. 
ACUTE PHASE PROTEIN 
In response to inflammation associated cytokines, the concentration of many plasma 
proteins increase during inflammatory states. C-reactive protein (CRP) is the first 
such protein to be recognized. It was initially detected in serum obtained from 
patients during the acute phase of pneumococcal pneumonia, hence the term ‘Acute 
phase protein’ (APP).  
Acute phase proteins are commonly defined as plasma proteins whose concentrations 
increase (positive acute phase proteins) by at least 25% during inflammatory states. 
In addition, it has been recognized that a number of negative acute phase proteins, 
whose concentrations decrease significantly under these circumstances. Altered 
production of proteins by hepatocytes is the main reason for all these changes.15 
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Inducers of acute phase gene expression 
The major stimuli for induction of acute phase changes are the inflammation 
associated cytokines. A wide variety of cytokines, growth factors, hormones, and 
other mediators have also been found to influence the expression of acute phase 
protein genes in liver or liver derived cells in culture. These molecules contribute to 
the inflammatory process at inflammatory sites largely by paracrine or autocrine 
manner but the induction of acute phase proteins changes results from bloodborne 
effects upon the liver. Of these cytokines, members of the IL-6 family, TNF (Tumour 
Necrosis factor)-α, IL-1, TGF (Transforming growth factor)-ẞ, and IFN (Interferon)-
γ have been studied elaborately.  
Gauldie et al., 1987 states that IL-6 is the major stimulator of most acute phase 
proteins. There is evidence that acute-phase cytokines and acute-phase reactants are 
released and associated with tissue breakdown in periodontal disease. Acute-phase 
response occurs in response to injuries, infections, or ischemic necrosis by releasing 
various acute-phase proteins, such as C reactive protein and fibrinogen. Data show 
that levels of various acute-phase proteins increased in periodontal disease in both 
gingival crevicular fluid (GCF) and plasma or serum (Keles et al, JOP 2014). 
Therefore, acute-phase proteins can be susceptibility markers in relation to 
inflammatory status. 
BIOMARKER 
A biomarker is a substance used to indicate a biologic state and gives an objective 
measure to evaluate the present and future disease activity. It is defined as – A 
substance that is measured objectively and evaluated as an indicator of normal 
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biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention.16Various biological media like saliva, serum and gingival crevicular 
fluid are used to determine biomarkers in periodontal health and disease. A single 
biomarker will not able to predict periodontal disease activity and severity. So a 
combination of biomarkers is necessaary.17 
Several molecules have been studied as potential biomarkers for periodontal disease 
including enzymes, cytokines, receptors, and other proteins. The biomarkers in 
gingival crevicular fluid (GCF) contains local biomarkers such as matrix 
metalloproteinases, acid/alkaline phosphatase etc., which can potentially provide 
information at the site level. While, the biomarkers in the blood, serum, or plasma 
contain systemic biomarkers, which can potentially, provide information at the 
patient level; and saliva contains both local and systemically derived markers and 
provides information at the patient level as well. 
Although the GCF has the advantage that it provides information at the site level, 
GCF collection is rather complicated and thus not convenient during routine dental 
procedures. Comparatively Saliva sample collection is easy, fast, non-invasive, and 
more convenient for the patient and the clinician. Saliva contains local and 
systemically derived markers of periodontal disease.18The blood cannot provide site-
specific information (Panagiota.G, Curr Oral Health Rep, 2015). Its sampling is 
generally more invasive than that of saliva. But it is relatively easy, fast, and can be 
performed outside of the dental office and as part of a routine general diagnostic 
check-up. Because of the simple, fast, and relatively non-invasive method of 
collection, salivary and blood diagnostic tests have the potential to be used for 
diagnosis and monitoring of periodontal disease at the patient level.19 
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INTERLEUKIN-6 
Cytokines are soluble mediators that aid cell-to-cell communication in immune 
responses. They include IFNs, chemokines, lymphokines, interleukins, TGF-b, 
colony-stimulating factors (CSF), and TNF which are characterized by functional 
redundancy and pleiotropy. Interleukins are cytokines that act primarily on 
leukocytes. Till date, nearly 40 interleukins have been identified. Interleukin-6 (IL-6) 
is a prototypical cytokine and an inflammatory biomarker. 
At first, IL-6 was identified as B-cell–stimulating factor 2 (BSF-2) in the culture 
supernatants of mitogen- or antigen stimulated peripheral blood mononuclear cells. It 
induce immunoglobulin production in Epstein–Barr virus–transformed B-cell lines or 
in Staphylococcus aureus Cowan 1–stimulated B cells.20In 1986 the gene encoding 
BSF-2 was cloned.21 
BSF-2 was found to be alike the hepatocyte-stimulating factor, the hybridoma growth 
factor, and IFNb-2. The molecule later became known as IL-6. Human IL-6 consists 
of 184 amino acids with two potential N-glycosylation sites and four cysteine 
residues. The core protein is about 20 kDa, and glycosylation accounts for the 21- to 
26-kDa size of natural IL-6(Hirano et al 1986). 
Biosynthesis and release 
IL-6 is produced by monocytes and macrophages after the stimulation of Toll-like 
receptors (TLRs) with distinct pathogen-associated molecular patterns (PAMP’s) 
during infectious inflammatory state. While, in non-infectious inflammations, such as 
burns or traumatic injuries, damage associated molecular patterns from damaged or 
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dying cells stimulate TLRs to produce IL-6. In addition to these cells, IL-6 can be 
produced by a variety of cells (Akira et al. 1993).22:  
1. Dendritic cells,  
2. T and B cells, 
3. Neutrophils,  
4. Mast cells,  
5. Fibroblasts,  
6. Synovial cells,  
7. Keratinocytes,  
8. Endothelial cells,  
9. Stromal cells,  
10. Mesangial cells,  
11. Glial cell neurons,  
12. Chondrocytes and osteoblasts,  
13. Smooth muscle cells,  
14. Adipocytes, and  
15. Other cells including tumor cells 
The synthesis of IL-6 is strictly regulated by transcriptional and post-transcriptional 
mechanisms (Tanaka et al. 2014). Transcriptional factors such as nuclear factor 
kappa B (NF-kB), nuclear factor IL-6 (NF-IL6), activation protein-1, and interferon 
regulatory factor-1 activate the IL-6 gene. 
The activation of receptors, such as glucocorticoid, estrogen, and aryl hydrocarbon, 
represses the IL-6 gene expression.  
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IL-6 stimulates hepatocytes to produce acute-phase proteins, such as C-reactive protein 
(CRP), serum amyloid A (SAA), fibrinogen, hepcidin, and a1-antichymotrypsin, and 
it reduces the production of fibronectin, albumin, and transferrin.23This increase in the 
levels of acute-phase proteins produces an emergency stress signal, which, contributes 
to host defense.  
Biological role  
The Biologic activities of IL-6 is explained in Fig.1. It also has redundancy property 
(with those of other members of the IL-6 family of cytokines).  
When tissue homeostasis is restored, the synthesis of IL-6 ceases. However, the 
dysregulated continuous production of IL-6 by distinct cell populations plays a 
pathologic role in various diseases. 
 
Figure 1. Pleiotropic activities of IL-6(Courtesy: The Biology and Medical 
Implications of Interleukin-6.Toshio Tanaka and Tadamitsu Kishimoto. Masters of 
immunology 2014.) 
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The immediate and transient expression of IL-6 contributes to host defence. When the 
source of stress is removed from the host, IL-6–mediated activation of the signal 
transduction cascade is ended by negative regulatory systems, such as ligand-induced 
internalization and degradation of gp130, and the recruitment of SOCS (Suppressors 
of cytokine signalling)24, resulting in the normalization of serum levels of acute-phase 
proteins such as CRP and SAA (Serum amyloid A). At the same time, IL-6 synthesis 
ceases. But the dysregulated, persistent IL-6 production, through mostly unknown 
mechanisms (one of which may be due to an imbalance between Arid5a and Regnase-
1) continues. This leads to the development of various diseases. The first association 
of IL-6 with disease development was demonstrated in a case of cardiac myxoma, in 
which the fluid obtained from the myxoma tissue of a patient contained a large quantity 
of IL-625.  
Kishimoto et al 2005 stated that Dysregulated IL-6 production also occurs in synovial 
fluids of rheumatoid arthritis, swollen lymph nodes of Castleman disease, myeloma 
cells, peripheral blood cells etc. and in many tumor cells.26 
Periodontitis is considered a local inflammatory/infectious process with systemic 
response, manifested by an increase of CRP, IL-6, and possibly hepcidin. Hepcidin is 
involved in iron homeostasis. It is hypothesized that individuals with chronic 
periodontitis without any systemic diseases, present lower haemoglobin(due to 
increased hepcidin level) levels than those with periodontal health. 
There have been various studies on IL-6 levels in saliva, serum and GCF in gingivitis 
and periodontitis patients. 
In 2004, Ide et al found that chronic periodontitis patients undergoing an episode of 
subgingival scaling showed a significant elevation in circulating TNF-α and IL-6.27 
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In 2010, Increased local (GCF and saliva) IL-6 were correlated with the presence of 
gingivitis (Becerik et al,28; Johanssen et al,29). 
Increased local (GCF and saliva) and systemic (serum) IL-6 levels were shown in 
periodontitis patients compared with healthy subjects (Geivelis et al, 1993;Costa et 
al, 2010). 
The levels of systemic IL-6 also seem to be affected by periodontal treatment, with an 
increase in association to the short-term inflammatory response to therapy (D’Aiuto et 
al,200530; Tonetti et al,200731)  
D’Aiuto et al, 200432; Marcaccini et al, 200933 stated that long-term reductions in 
the level of IL-6 were observed, when a clinical improvement in the periodontal status 
was obtained. 
In studies done by Loos et al.,34Anila Prabhu et al.,35Ebersole et al.,36 and Ebersole 
and Cappelli,37it was found that the periodontitis patients had higher CRP and IL-6 
levels when compared to the periodontally healthy subjects. 
Sun et al in 2009, found that the Patients with aggressive periodontitis have 
significantly elevated levels of plasma C-reactive protein and interleukin-6.38 
In 2009, Gani, in his study found that Periodontitis results in higher systemic levels of 
CRP and IL-6.These elevated inflammatory factors may increase inflammatory activity 
in atherosclerotic lesions and potentially increasing the risk for cardiovascular events.39 
Nakajima et al. in the year 2010 reported that CRP and IL-6 were significantly higher 
in periodontitis patients compared to healthy controls.40 
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In a study by Keles et al 2014, it was found that IL-6 levels were higher in chronic 
periodontitis patients when compared with gingivitis patients.41 
In a study by Haro et al (2016), it was found that, the number of teeth with deepened 
periodontal pockets was associated with elevated serum IL-6 levels among subjects 
with an unfavourable lipid composition.42 
In a study by Solomon et al 2016, it was found that IL-6 levels were higher in patients 
with periodontitis and atherosclerosis and it improved following non-surgical 
periodontal therapy.43 
Beck et al in 2017 in his study found that high gingival inﬂammation, tooth loss, severe 
tooth loss, and severe disease PPC(Periodontal Profile Class) components were 
signiﬁcantly associated with diabetes, coronary heart disease (CHD), high-sensitivity 
C-reactive protein, and interleukin (IL)-6, while only severe disease was associated 
with stroke.44 
Delange in 2018 found that, Severe periodontitis was signiﬁcantly associated with 
increased levels of IL-6 compared with those with none or mild periodontitis.45 
HEPCIDIN AND ANEMIA OF INFLAMMATION 
The anemia of chronic disease refers to the compromised production of erythrocytes 
associated with chronic inflammatory states, including cancer, chronic infection, or 
autoimmune diseases. Anaemia can also occur in the setting of severe, acute 
inflammation, such as critical illness, or in cases of milder but persistent inflammatory 
signals that occur in obesity, aging, and kidney failure. For these reasons, the name 
“anaemia of inflammation” may be more suitable than anaemia of chronic disease. It 
is considered the second most common form of anaemia worldwide. 
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Hepcidin is a potent regulator of iron homeostasis and is a possible mediator of the 
anemia of inflammation46. Hepcidin mRNA is induced in hepatocytes in response to 
inflammation47. The cytokines interleukin-1b (IL-1b) and interleukin-6 (IL-6)48 have 
been demonstrated to be primarily responsible for hepcidin induction. 
Serum and plasma hepcidin levels are elevated in conditions such as chronic kidney 
disease, inflammation, and multiple myeloma49. Hence, Hepcidin can be used as a 
therapeutic target for the treatment of AI (ANAEMIA OF INFLAMMATION) 
50,51,52,53. Mice54,55 and humans56 that produce elevated levels of hepcidin develop 
anemia that shares some features of Anaemia of inflammation (normocytic, 
normochromic type)57. 
Anemia of inflammation is associated with IL-6 in patients with rheumatoid arthritis58, 
systemic lupus erythematosus59, and the geriatric syndrome of frailty60. IL-6 not only 
induces hepcidin in these disease states but studies have proven that it also has direct 
oppressive effects on erythroid development in cultures61,62.  
As a result, the anaemia in these disease state is found to be multifactorial, resulting 
from hepcidin-mediated iron restriction as well as from direct effects of IL-6, on 
erythroid progenitor cells. 
Pathogenesis of anemia of inflammation 
Anaemia of inflammation is multifactorial, and the precise pathology is yet to be 
defined63,64. Erythrocyte survival is shortened due to macrophage activation by 
inflammatory cytokines and hemolysis. Erythropoiesis is impaired by inflammatory 
cytokines by inhibition of the production and function of erythropoietin, and by direct 
inhibition of erythroid progenitor cell proliferation and differentiation. Inflammatory 
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cytokines also induce the production of iron regulatory hormone hepcidin. It suppresses 
the iron exporter ferroportin to restrict the supply of iron for erythropoiesis. 
HEPCIDIN 
Hepcidin65 is a peptide discovered in 2001 by park et al. It is the key mediator of 
anaemia of inflammation.66,67 It is a conserved 25–amino acid peptide produced in the 
liver and detectable in blood and urine.68 Mice lacking hepcidin mRNA developed iron 
overload in the liver and pancreas, whereas iron scarcity in the macrophage-rich 
spleen.69 Transgenic mice with overproduction of hepcidin died at birth of severe iron 
deficiency.70 In these studies it was suggested that hepcidin inhibits iron absorption in 
the small intestine, the release of recycled iron from macrophages, and transport of iron 
across the placenta. In human studies, the patients with large hepatic adenomas and 
iron-refractory anaemia (which otherwise cannot be explained), overexpressed 
hepcidin mRNA in their tumours. 
HEPCIDIN PRODUCTION: 
The hormone hepcidin is produced in a two-step process consisting of conversion of 
an 84-amino-acid–long peptide, preprohepcidin by N-terminal cleavage of a 24-amino-
acid signal peptide to give rise to prohepcidin. It is followed by a second cleavage of a 
35-amino-acid peptide to produce the active compound 25-amino-acid hepcidin 
(hepcidin-25). 
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HEPCIDIN REGULATION: 
Hepcidin transcription in the liver is controlled by a multifaceted interchange of signals 
between inflammation, iron status, and erythropoietic drive71,72 which is explained in 
Fig.2.  
1) Circulating and tissue iron-upregulates hepcidin and limit further iron entry, 
2) Erythropoietic drive-suppresses hepcidin and increases iron availability for 
erythrocyte production.  
3) Hepcidin induction by inflammation is thought to have evolved by nature to 
sequester iron from pathogenic microorganisms. 
Hepcidin regulation by inflammation 
Inflammatory cytokines (particularly IL6) regulate hepcidin transcription through the 
JAK-STAT3 pathway. There is a primary role for IL-6 in hepcidin induction in many 
infections, which include, streptococcus pneumonia and influenza A and most 
extracellular pathogen-associated molecular patterns. IL-6 knockout mice showed a 
lessened/absent hepcidin induction to these stimuli73. IL-22 has a minor role in hepcidin 
induction by Lipopolysaccharides74. IL-1 can also regulate hepcidin, either by inducing 
IL-6 dependent or by IL6-independent mechanisms75,76. In a study it was shown that 
IL-1β stimulates hepcidin and induces hypoferremia in mice by an unproven alternate 
pathway. In which there is induction of SMAD1/5/8 signalling. This pathway was 
thought to be the mechanism for hepcidin induction by commensal intestinal bacteria 
(relevant to inflammatory bowel disease).77 
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Figure2. Regulation of Hepcidin by various pathways (Courtesy: Hepcidin 
Regulation in the Anemia of Inflammation. Chia-Yu Wang and Jodie L. Babitt. 
CurrOpinHematol 2016) 
Since, periodontitis is considered a local inflammatory/infectious process with a 
systemic response, it is speculated that patients with chronic periodontitis (not 
influenced by any systemic diseases) present lower hemoglobin levels than those with 
periodontal health owing to increased production of hepcidin (Holtfreter et al, 2010).78 
In a study by Shin Yu Lu et al in 2009, a dramatic recovery from severe anaemia after 
resolution of severe periodontitis was observed.79 
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In 2010, a study by Gokhale et al, it was concluded that patients suffering from chronic 
periodontitis have a lower number of erythrocytes and hemoglobin compared to healthy 
controls.80 
The findings of the study by Anand et al in 2013, suggested that patients with 
generalized aggressive periodontitis tend to have lower erythrocyte counts and lower 
hemoglobin levels compared with periodontally healthy controls.81 
Patel in 2013, in his study concluded that like any other chronic condition, chronic 
periodontitis can lead to ACD (Anaemia of Chronic disease). It also provides evidence 
that non-surgical periodontal therapy can improve the anemic status of patients with 
chronic periodontitis.82 
In 2013, Jenabian reported that, a correlation was observed between some 
hematological parameters associated with anemia and moderate chronic 
periodontitis.83 
In 2013 Rao et al in a study found that there was statistically significant relation 
between oral hygiene, gingival inflammation, haemoglobin and total iron binding 
capacity in both the healthy and aggressive periodontitis group.84 
In a study by Hedge et al 2014, Data analysis showed that patients with chronic 
periodontitis had lower values of hematocrit, number of erythrocytes, and hemoglobin 
and increased ESR level compared to healthy group. No remarkable differences in 
levels of MCH, MCHC and MCV were found between test and control group.85 
Results of the study by Nubesh Khan et al, showed that patients suffering from chronic 
periodontitis had lower values of hemoglobin compared to healthy controls.86 
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Kolte et al in his study in 2014, concluded that periodontitis, like other chronic 
conditions, may lead to anemia as the number of erythrocytes is lower in affected 
patients.87 
In 2016, Anumolu et al reported that, there was a decrease in Hb and erythrocyte 
counts and increase in white blood corpuscles counts in chronic generalized 
periodontitis when compared to healthy controls and chronic generalized gingivitis 
group. It was concluded that the treatment of periodontitis can lead to an improvement 
in hematocrit and other related blood parameters in chronic generalized periodontitis 
patients with anemia.88 
In a study by Mann et al in 2017, remarkable hematological differences in EC 
(Erythrocytes), HGB (Haemoglobin concentration), MCV(Mean Corpuscular Volume) 
and MCH(Mean Corpuscular Haemoglobin) between healthy periodontium and 
chronic periodontitis subjects indicating mild anaemia were seen.89 
In a study by Parihar et al in 2018, it was concluded that chronic periodontitis like 
any other chronic disease can cause anemia.90 
STUDIES ON HEPCIDIN LEVELS 
In 2011, Vilela et al found that Treatment of chronic periodontitis decreases serum 
prohepcidin levels in patients with chronic kidney disease.91 
In 2015, Carvalho et al investigated the relationship between hepcidin and chronic 
periodontitis patients. It was the first investigation to estimate the association between 
periodontitis and the levels of hepcidin and haemoglobin in the blood.92 
In the group of individuals with chronic periodontitis, both hematocrit values and those 
of serum iron were lower than in participants without periodontitis. The lowest 
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hematocrit value in this group can be attributed to less number of red blood cells in 
individuals with periodontal infection (Kolte et al, 2014; Patel et al, 2014). 
The hypothesis generated in this study is that individuals without other diseases except 
periodontitis present lower levels of hepcidin and hemoglobin than those with 
periodontal health.  
The rationale underlying this hypothesis is: In response to periodontal infection, cells 
from host defense system release immune-inflammatory mediators, such as IL-6, PGE2 
etc., which stimulate the production of an acute phase protein called hepcidin (Loos, 
2005; Forner et al,2006; Yazdi et al, 2013). Hepcidin plays a role in organic defense 
and homeostatic regulation of iron metabolism (Ganz, 2003). 
This study showed that the level of serum hepcidin in individuals diagnosed with 
periodontitis was 65.6±14.3 ng ml-1, and for those without such infection was 
60.9±13.0 ng ml-1. 
In 2018, Guo et al, studied the Serum and salivary ferritin and Hepcidin levels in 
patients with chronic periodontitis and type 2 diabetes mellitus. The results were, 
Serum ferritin and hepcidin levels in the chronic periodontitis (CP) and CP with T2DM 
groups were higher than in the control group. Serum hepcidin and serum ferritin are 
linearly correlated. Serum hepcidin/ferritin values in the CP with T2DM group were 
significantly lower than those in the T2DM and control groups. Moreover, salivary 
ferritin levels in the CP and T2DM groups were higher than those in the control group. 
There was a positive correlation between salivary ferritin and serum ferritin. Hepcidin 
concentrations were relatively low in saliva.93 
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PERIODONTAL PHASE I THERAPY AND LEVELS OF SYSTEMIC 
PARAMETERS 
Periodontitis is associated with elevated serum inflammatory markers Pussinen et al 
2007. This suggests that periodontitis may have an impact on systemic health and the 
efforts to maintain or restore periodontal health may contribute to systemic health.  
Studies have shown that biological markers of systemic conditions like atherosclerosis 
are more prevalent in periodontitis patients Wick et al 2013. 
The currently available data on periodontal-systemic associations are rather 
heterogeneous Linden et al 2013, and the evidence that periodontal therapy has an 
impact on systemic health is limited and not yet established D’Aiuto et al 2013.  
A few studies have tried to explain whether successful periodontal treatment can reduce 
the levels of serum markers and have yielded inhomogeneous results.  
In a preliminary intervention study it was found that standard scaling and root planing 
(SRP) may change the levels of IL-6 and C-reactive protein D’Aiuto et al 2004. In a 
comparative study, SRP reduced levels of IL-6 and C-reactive protein, D’Aiuto et al 
2005.  
In another study by Teles et al in 2012 it was found that periodontal therapy improved 
clinical and microbiological parameters but did not influence the levels of serum 
biomarkers.  
Agarwal et al in 2009 in a study found that, correction of periodontal inflammation 
resulted in a significant increase in hemoglobin levels and erythrocyte counts. The 
erythrocyte sedimentation rate showed a reduction in periodontal inflammation. There 
was a significant, but much lesser, improvement in MCV, MCH and MCHC values. 
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These results showed that treatment of periodontitis leads to an improvement in 
hematocrit and other related blood parameters in chronic generalized periodontitis 
patients with anemia.94 
Behle et al in 2009 in a study found that, Periodontal therapy resulted in an overall 
reduction of systemic inflammation, but the responses were inconsistent across 
subjects.95 
Offenbacher et al. in 2009 reported that there was no significant difference in serum 
hsCRP at 6 months between patients receiving scaling and root planing and patients 
receiving community care96. 
In 2009 Marcaccini et al in a study found that, Circulating Interleukin-6 and High-
Sensitivity C-Reactive Protein decrease after Periodontal Therapy in otherwise Healthy 
Subjects.97 
Marcaccini et al in 2009 in another study showed that MMP-3, MMP-8, and MMP-9 
concentrations were higher in periodontitis patients compared with healthy controls. In 
addition, non-surgical periodontal therapy significantly decreased plasma MMP-8 and 
MMP-9 concentrations by 35% and 39% compared to baseline; both results were 
statistically significant. The results suggested that plasma MMP-3, MMP-8, and MMP-
9 may be useful biomarkers for the diagnosis of diseased individuals.98 
In a pilot intervention study, Duarte et al. in 2010 evaluated the serum concentration 
of several cytokines in patients with generalized chronic periodontitis, generalized 
aggressive periodontitis and healthy controls, and the effect of periodontal therapy on 
these cytokines 6 months after treatment. They found that TNF-alpha and IL-17 
concentrations were higher in aggressive periodontitis patients compared to healthy 
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controls or chronic periodontitis, while there was no difference in other cytokines. In 
addition, nonsurgical periodontal therapy significantly decreased plasma TNF-alpha 
and IL-17 compared to baseline; both results were statistically significant; however, 
TNF-alpha levels remained elevated compared to healthy controls. The results 
suggested that serum TNF-alpha and IL-17 may be useful biomarkers for the 
differential diagnosis between aggressive and chronic periodontitis, while IL-17 may 
be useful for monitoring response to periodontal treatment in aggressive 
periodontitis.99 
Pradeep et al in 2010, in a study found that Serum oncostatin M was significantly 
higher in patients with chronic periodontitis compared to healthy and gingivitis 
controls. Oncostatin M levels significantly decreased 2 months after nonsurgical 
periodontal therapy, and this decrease correlated with improvement in clinical 
parameters.100 
Shimada et al in 2010 in a study on the Effect of Periodontal Treatment on Serum 
Leptin, Interleukin-6, and C-Reactive protein found that Periodontal treatment was 
effective in reducing serum leptin, IL-6, and CRP levels.101 
In 2012, Malhotra et al in a study found that lower values of EC, Hb and HCT were 
seen in periodontitis group, which tends to improve after completion of periodontal 
therapy.102 
Rastogi et al 2012 found that in patients with chronic periodontitis and known 
coronary artery disease, SRP reduced high-sensitivity C-reactive proteins (hsCRPs) 
and white blood cell counts. 
Review of literature 
 
24 
 
Koromantzos, Makrilakis, Dereka, in their study in 2012, concluded that Effective 
non-surgical periodontal treatment of participants with type 2 DM (Diabetes Mellitus) 
and moderate to severe periodontal disease improved significantly the HbA1c levels.103 
In 2014, Musalaiah et al in a study on Evaluation of nonsurgical periodontal therapy 
in chronic periodontitis patients with anemia by estimating hematological parameters 
and high sensitivity C-reactive protein levels showed that there was a significant 
increase in Hb levels, RBC count and PCV(Packed cell volume) from baseline to 6 
months after nonsurgical periodontal therapy. There was significant decrease in levels 
of ESR and hs-CRP levels after nonsurgical periodontal therapy. There was a 
significant decrease in PPD, scores of PI and GI and significant increase in CAL 
gain.104 
In 2016 Solomon et al in a study on the effect of non-surgical therapy on C reactive 
protein and IL-6 serum levels in patients with periodontal disease and atherosclerosis 
found that after the non-surgical periodontal therapy, the values of periodontal 
parameters and the levels of CRP and IL-6 had improved. 
Jain et al in 2016, in a study on the effect of periodontal treatment on red blood cell 
parameters in patients with chronic periodontitis, found that periodontal therapy in 
patients with chronic periodontitis may lead to an increase in levels of red blood cells, 
hemoglobin concentration and packed cell volume together with decrease in values of 
ESR.105 
Balli 2016 in a study on Chemerin and interleukin-6 levels in obese individuals 
following periodontal treatment found that greater values of chemerin and IL-6 were 
observed in obese individuals compared to their non-obese controls, and in individuals 
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with CP compared to their periodontal-healthy controls, which decreased following 
therapy.106 
Yang 2017 in a study showed that Non-surgical periodontal treatment significantly 
reduced the serum ACPA (Anti-Citrullinated protein Antibodies) and TNF-α levels in 
CP patients, particularly in patients with generalized CP. There was a positive 
correlation between the number of extracted teeth and the reduction in the serum ACPA 
and IL-1β levels after non-surgical periodontal treatment.107 
Haghoo JM 2018, in his study found that the amount of hemoglobin and red blood 
cells one month after treatment procedure noticeably increased in comparison to the 
base line. Also haematocrit showed improvement in laboratory results. While, LDL 
(Low density lipoprotein)/VLDL (Very low density lipoprotein) decreased in its 
value.108 
The literature shows that periodontal disease is a local infection with a systemic 
inflammatory response. It has been shown that periodontitis is associated with various 
systemic complications, one of which is anaemia of chronic disease. But the exact 
mechanism for the development of anaemia of chronic disease due to periodontal 
disease is still unknown. Hepcidin is shown to be the key regulator of anaemia due to 
various chronic diseases. The relationship of hepcidin with periodontal disease is not 
established till now. Our study aims to, 
 Establish the relationship between periodontal disease and serum Hepcidin and 
IL-6 levels.  
 To evaluate the effectiveness of phase 1 periodontal therapy in reducing serum 
hepcidin and IL-6 levels. 
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MATERIALS AND METHODS 
STUDY POPULATION: 
The study population was selected from the outpatient section of the Department of 
Periodontology, Tamil Nadu Government Dental College and Hospital, Chennai.   
STUDY DESIGN: 
The study was of a case control type. The study participants were recruited 
prospectively in this study.   
OPERATIONAL DEFINITIONS: 
Chronic periodontitis- Chronic periodontitis has been defined as an infectious 
disease resulting in inflammation within the supporting tissues of the teeth, 
progressive attachment loss and bone loss.  
Aggressive periodontitis - Aggressive periodontitis is the disease of the 
periodontium occurring in an otherwise healthy individual which is characterised by a 
rapid loss of alveolar bone about more than one tooth of the permanent dentition. 
Serum hepcidin - Hepcidin is a cationic peptide that is rich in cysteine. It is 
synthesized by the liver and excreted by the kidney and its main function is 
homeostatic regulation of iron metabolism. 
Interleukin – 6 – it is a signalling protein/cytokine produced by several cells 
including macrophages, neutrophils, keratinocytes, and fibroblasts, in response to 
stimulus such as infection and trauma 
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Plaque Index (Sillness & Loe 1964) - An index for estimating the status of oral 
hygiene by measuring the microbial deposits which occurs adjacent to gingival 
margins 
Bleeding Index (Ainamo & Bay 1975) - An assessment tool used to verify the 
presence of gum inflammation based on bleeding that occurs around gingival sulcus 
upon gentle probing with the standard periodontal probe. 
Probing pocket Depth – Measurement of depth of gingival sulcus or periodontal 
pocket determined by measuring the distance from the gingival margin to the base of 
the sulcus or pocket with calibrated periodontal probe. 
SAMPLING PROCEDURE: 
The sampling was done by simple random sampling. 
SAMPLE SIZE: 
A total of 45 subjects were selected for the study. 
              Group I- 15 subjects with healthy periodontium. (Control group) 
              Group II- 15 subjects with chronic periodontitis (study group) 
              Group III- 15 subjects with aggressive periodontitis (study group) 
ELIGIBILITY CRITERIA: 
Inclusion criteria - 
 Age 15– 55 years. 
 Either sex.  
 Minimum of 20 teeth should be present. 
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 Control group: group I- periodontally healthy individuals 
 Study group:  
              a) Group II- patients with chronic periodontitis, with clinical attachment loss 
greater than or equal to 5mm, involving >30% of teeth present. 
              b) Group III- patients with aggressive periodontitis with attachment loss 
affecting at least 3 permanent teeth, other than the first molars and incisors 
Exclusion criteria – 
 Smokers. 
 Infections(acute and chronic) 
 Patients with systemic diseases, Organ transplantation and auto-immune 
diseases 
 Medically compromised patients such as uncontrolled diabetes, 
hypertension, immunosuppression, bleeding disorders, cancer, stroke and 
severe osteoporosis.  
 Patients with iron supplements to treat anaemia 
 Patient who underwent periodontal treatment in past 6 months.  
 Usage history of NSAIDs (non-steroidal anti-inflammatory drugs)  and 
antibiotics within 3 months prior to the study  
 Pregnancy and lactation 
 Patients under bisphosphonates medication 
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ARMAMENTARIUM: 
FOR CLINICAL 
EXAMINATION 
FOR BLOOD SAMPLE 
COLLECTION 
FOR PHASE 1 THERAPY 
Mouth mirror Sterile cotton Mouth mirror 
Curved explorer Surgical spirit Curved explorer 
William’s probe Disposable 2 ml syringe 
with 22 gauge needle 
William’s probe 
Dental tweezers  Hand-scalers 
Sterile cotton rolls  Ultrasonic scaler unit 
(Manufacturer: 
woodpecker) 
Sterilized disposable 
gloves 
 Curettes 
Disposable head-caps  Kidney tray 
Disposable facemasks  Sterile cotton rolls 
Patient apron  Sterile gauze 
  Disposable syringe with 
24 gauge needle 
  Local anaesthetic solution 
  0.9% normal saline 
solution 
  Patient apron 
 
Materials and methods 
 
30 
 
Selected patients in both study and control group were subjected to detailed case 
history, and clinical examination. 
Clinical parameters assessed were: 
 Plaque Index  
 Bleeding on probing. 
 Probing pocket depth  
 Clinical attachment levels at four sites (mesial, facial , distal , palatal / 
lingual) 
CLINICAL PARAMETER ASSESSMENT: 
The following clinical parameters were evaluated for all the subjects:  
1. Plaque index – Silness and Loe 1964 
2. Gingival bleeding index – Ainamo and Bay 1975  
      3. Probing pocket depth in mm (PD) – Carranza 12th ed 
      4. Clinical attachment level in mm (CAL) – Carranza 12th ed 
Plaque Index (Silness and Loe)  
All teeth were examined at 4 sites each (disto-facial, facial, mesio-facial, lingual / 
palatal) and were scored as, 
Scoring Criteria:  
Score 0: No plaque in the gingival area.  
Score 1: A film of plaque adhering to the free gingival margin and adjacent area of 
the tooth. The plaque is recognized only by running a probe across the tooth surface.  
Score 2: Moderate accumulation of plaque within the gingival pocket and on the 
gingival margin and / or adjacent tooth surface that can be seen by the naked eye.  
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Score 3: Abundance of soft deposits within the gingival pocket and / or on the 
gingival margin and adjacent tooth surface.  
Calculation:  
Plaque index per tooth = Total score/4  
Plaque index per individual ═ Total PI per tooth / Total number of teeth examined  
Interpretation:  
Score 0 – Excellent oral hygiene  
0.1 to 0.9 – Good oral hygiene  
1.0 to 1.9 – Fair oral hygiene  
2.0 to 3.0 - Poor oral hygiene 
Gingival Bleeding Index (Ainamo & Bay)  
Starting distobuccally, the probe was gently inserted into the sulcus and run to the 
buccal and mesial surfaces of every tooth at an angle of about 45º. This was repeated 
for all the teeth present. Similarly probing was carried out at palatal/lingual sites. The 
total number of bleeding sites per tooth was thus recorded for every tooth except the 
third molar.  
Scoring Criteria:  
Positive score (1) - Presence of bleeding within 10 seconds  
Negative score (0) - Absence of bleeding 
% of bleeding sites =  Total number of positive score x 100 
Total number of surfaces of all teeth 
Probing Pocket Depth (PPD)  
Probing Pocket Depths were measured from the gingival margin to the base of the 
pocket in mm using William’s Periodontal Probe. The probe was walked within the 
gingival sulcus along the circumference of the tooth. Keeping the probe parallel to the 
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long axis of the selected tooth, six measurements were made per tooth (Mesiobuccal, 
Distobuccal, Midbuccal, Mesiolingual, Distolingual and Midlingual). 
Clinical Attachment Level (CAL) 
Clinical Attachment Level was measured from the Cemento – Enamel Junction (CEJ) 
to the base of the pocket using William‘s Periodontal Probe.  
When the gingival margin was located on the anatomic crown, the level of the 
attachment was determined by subtracting from the probing depth, the distance from 
the gingival margin to the CEJ (Cemento enamel junction). If both were the same, the 
loss of attachment was calculated to be zero.  
When the gingival margin coincided with the CEJ, the loss of attachment was 
calculated as equalling the probing depth.  
When the gingival margin was located apical to the CEJ, the loss of attachment was 
greater than the probing depth and therefore the distance between the CEJ and the 
gingival margin were added to the PD.  
Three measurements were made on the buccal aspect and three on the lingual aspect 
of each tooth – total of six sites per tooth (Mesiobuccal, Midbuccal, Distobuccal, 
Mesiolingual, Midlingual, and Distolingual). 
RADIOGRAPHIC PARAMETERS: 
 Radiographs were taken to assess the bone loss. 
ROUTINE BLOOD INVESTIGATIONS DONE WERE: 
 Haemoglobin percentage- Hb% 
 Bleeding time(BT) 
Materials and methods 
 
33 
 
 Clotting time(CT) 
 Total leukocyte count 
 Differential leukocyte count 
 Random blood sugar 
PHASE-I PERIODONTAL THERAPY: 
 After clinical examination and oral prophylaxis, phase-I periodontal 
therapy was done in four weeks. 
 Routine blood investigations were done for all the subjects before doing 
treatment 
 A test dose of 0.5ml of 2% lignocaine solution was administered to the all 
the subjects. Local anaesthetic solution was then injected at diseased sites 
and scaling and root planing was done. Oral hygiene instructions (OHI) 
were given. 
 Then the patients in study groups were kept under maintenance phase and 
were recalled after three months. Again clinical examination and blood 
sample collection was done. 
ESTIMATION OF SERUM HEPCIDIN AND INTERLEUKIN-6 LEVELS: 
Blood Samples were collected for the control group at baseline and for the study 
groups at baseline before phase-I therapy and 3 months after phase-I therapy. 
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 2ml of blood sample was drawn from the ante cubital vein, using a 2 
ml syringe with 22 gauge needle, under aseptic conditions, and 
transferred to sterile test tubes coated with EDTA. 
Blood samples were taken to IBMS (Institute of Biomedical Science), Chennai, for 
estimation of serum hepcidin and interleukin-6 levels.   
HUMAN HEPCIDIN ELISA KIT (Bioassay Technology Laboratory) 
This sandwich kit is for the accurate quantification of human Hepcidin (also known 
as HEPC) in serum, plasma, cell culture supernates, cell lysates, tissue homogenates.  
ASSAY PRINCIPLE: 
This kit is an Enzyme-Linked Immunosorbent Assay (ELISA). HEPC is added to the 
wells pre-coated with HEPC monoclonal antibody. After incubation a biotin-
conjugated anti-human HEPC antibody is added and binds to human HEPC. After 
incubation, unbound biotin-conjugated anti-human HEPC antibody is washed away 
during washing step. Streptavidin-HRP is added and binds to the biotin-conjugated 
anti-human HEPC antibody. After incubation unbound Streptavidin-HRP is washed 
away during a washing step. Substrate solution is then added and color develops in 
proportion to the amount of human HEPC. The reaction is terminated by addition of 
acidic stop solution and absorbance is measured at 450 nm. 
REAGENTS USED: 
Standard Solution (4800pg/ml)-0.5ml   
Pre-coated ELISA Plate-12 * 8 well strips  
Standard Diluent-3ml  
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Streptavidin-HRP-6ml  
Stop Solution-6ml  
Substrate Solution A -6ml  
Substrate Solution B -6ml   
Wash Buffer concentrate (30x) -20ml   
Biotin-Conjugate Anti-human HEPC Antibody -1ml  
OTHER MATERIALS REQUIRED:  
1. 37°C±0.5°C incubator   
2. Microplate reader with 450 ± 10nm wavelength filter     
3. Precision pipettes and disposable pipette tips     
4. Clean tubes     
5. Deionized or distilled water    
6. Absorbent paper 
SAMPLE COLLECTION: 
Serum was allowed to clot for 10-20 minutes at room temperature. Centrifuged at 
2000-3000 RPM for 20 minutes.  
ASSAY PROCEDURE: 
1. 50μl standard was added to standard well.  
2. 40μl sample was added to sample wells and then 10μl anti-HEPC antibody was 
added to sample wells, then 50μl streptavidin-HRP to sample wells and standard 
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wells（Not blank control well. It was mixed well. The plate was covered with a 
sealer. Gently vibrated to mix well. It was Incubated 60 minutes at 37°C.  
3. The sealer was removed and the plate was washed 5 times with wash buffer. Wells 
were soaked in wash buffer for 30 seconds to 1 minute for each wash. The plate was 
blotted onto paper towels or other absorbent material.  
4. 50μl substrate solution A was added to each well and then 50μl substrate solution 
B was added to each well. The plate was covered with a new sealer for 10 minutes at 
37°C at room temperature in the dark.  
5. 50μl Stop Solution was added to each well, the blue color changes into yellow 
immediately.  
6. The optical density (OD value) of each well was determined immediately using a 
microplate reader set to 450 nm within 30 min after adding the stop solution. 
CALCULATION OF RESULTS: 
A standard curve was constructed by plotting the average OD for each standard on 
the vertical (Y) axis against the concentration on the horizontal (X) axis and a best fit 
curve through the points on the graph was drawn. These calculations can be best 
performed with computer-based curve-fitting software and the best fit line can be 
determined by regression analysis. If the standard had been diluted, the concentration 
read from the standard curve was multiplied by the dilution factor.   
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HUMAN INTERLEUKIN-6 ELISA KIT (Bioassay Technology Laboratory) 
This sandwich kit is for the accurate quantification of Human Interleukin 6（also 
known as IL-6）in serum, plasma, cell culture supernates, cell lysates, tissue 
homogenates. 
This kit is a Enzyme-Linked Immunosorbent Assay (ELISA). IL-6 is added to the 
wells pre-coated with IL-6 monoclonal antibody. After incubation a biotin-conjugated 
anti-human IL-6 antibody is added and binds to human IL-6.After incubation 
unbound biotin-conjugated anti-human IL-6 antibody is washed away during a 
washing step. Streptavidin-HRP is added and binds to the biotin-conjugated anti-
human IL-6 antibody. After incubation unbound Streptavidin-HRP is washed away 
during a washing step. Substrate solution is then added and color develops in 
proportion to the amount of human IL-6.The reaction is terminated by addition of 
acidic stop solution and absorbance is measured at 450 nm.  
REAGENTS USED: 
Standard Solution (640ng/L)-0.5ml  
Pre-coated ELISA Plate-12 * 8 well strips  
Standard Diluent-3ml  
Streptavidin-HRP-6ml  
Stop Solution-6ml  
SubstrateSolution A-6ml  
Substrate Solution B -6ml  
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Wash Buffer concentrate (30x)-20ml   
Biotin-Conjugate Anti-human IL-6Antibody -1ml  
OTHER MATERIALSREQUIRED: 
1. 37°C±0.5°C incubator  
2. Microplate reader with 450 ± 10nm wavelength filter  
3. Precision pipettes and disposable pipette tips  
4. Clean tubes     
5. Deionized or distilled water  
6. Absorbent paper 
SAMPLE COLLECTION: 
Serum was allowed to clot for 10-20 minutes at room temperature. Centrifuged at 
2000-3000 RPM for 20 minutes.  
ASSAY PROCEDURE: 
1. 50μl standard was added to standard well.  
2. 40μl sample was added to sample wells and then 10μl anti-IL-6 antibody was 
added to sample wells, then 50μl streptavidin-HRP to sample wells and standard 
wells（Not blank control well). The ingredients are mixed well. The plate was 
covered with a sealer. Incubated 60 minutes at 37°C.  
3. The sealer was removed and the plate is washed 5 times with wash buffer. The 
wells were soaked in wash buffer for 30 seconds to 1 minute for each wash. The plate 
was blotted onto paper towels or other absorbent material.  
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4. 50μl substrate solution A was added to each well and then 50μl substrate solution 
B was added to each well. The plate was covered with a new sealer and incubated for 
10 minutes at 37°Cat room temperature in the dark.  
5. 50μl Stop Solution was added to each well, the blue color changes into yellow 
immediately.  
6. The optical density (OD value) of each well was determined immediately using a 
microplate reader set to 450 nm within 30 min after adding the stop solution. 
CALCULATION OF RESULTS: 
A standard curve was constructed by plotting the average OD for each standard on 
the vertical (Y) axis against the concentration on the horizontal (X) axis and a best fit 
curve through the points on the graph was drawn. These calculations can be best 
performed with computer-based curve-fitting software and the best fit line can be 
determined by regression analysis. If the standard had been diluted, the concentration 
read from the standard curve was multiplied by the dilution factor.  
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PHOTOGRAPHS 
 Photograph 1: Armamentarium for examination of the patient 
 
 
 
 
 
 
 
 
 
 
 
 
Photograph 2 & 3: Armamentarium for Phase I therapy and venous blood 
collection 
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Photograph 4: Venous blood collection 
 
 
 
 
 
 
 
 
 
 
 
 
 
Photograph 5: Group I- healthy subject at baseline 
 
 
 
 
 
 
 
 
 
 
 
 
 
Photographs 
 
42 
 
Photograph 6: Group II-Chronic periodontitis patient at baseline 
 
 
 
 
 
 
 
 
 
Photograph 7: Group II-Chronic periodontitis patient at 3 months after  
Phase-I therapy 
 
 
 
 
 
 
 
 
 
Photograph 8: Orthopantomograph of the chronic periodontitis patient 
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Photograph 9: Group III-Aggressive periodontitis patient at baseline 
 
 
 
 
 
 
 
 
 
Photograph 10: Group III-Aggressive periodontitis patient at 3 months after 
phase-I therapy 
 
 
 
 
 
 
 
 
 
Photograph 11: Orthopantomograph of the Aggressive periodontitis patient 
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Photograph 12: ELISA plate with wells 
 
 
 
 
 
 
 
 
Photograph 13: ELISA reader 
 
 
 
 
 
 
 
 
 
Photograph 14: Pipettes 
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Photograph 15: Storage refrigerator for serum samples 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Photograph 16: Cooling centrifuge 
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STATISTICAL ANALYSIS 
In the present study, 45 subjects were selected, of which 15 were categorized as Group I 
which consisted of healthy subjects, 15 were categorized as Group II which consisted of 
patients with chronic periodontitis and another 15 were categorized as Group III which 
consisted of patients with aggressive periodontitis. The mean average of age in group I is 
41.2±8.7, group II is 43.13±5.45 and group III is 25.8±5.6. The clinical parameters assessed 
were plaque index, gingival bleeding index, pocket probing depth, clinical attachment level 
and laboratory parameters assessed were serum IL-6,hepcidin level at baseline in group I, at 
baseline and 3 months after phase I therapy in group II and III.  
The statistical analysis was done using the computer software program SPSS version 20.0 
(Statistical Package for Social Science, Version 20). 
Statistical Tests used were: 
1. Paired t test 
2. Unpaired t test 
3. ANOVA  
4. Post HOC analysis- Tukey’s analysis 
 
PAIRED t TEST 
It is applied to paired data of independent observations from one sample only when each 
individual gives a pair of observations 
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UNPAIRED t TEST 
This test is applied to unpaired data of independent observations made on individuals of two 
different or separate groups or samples drawn from two populations, to test if the difference 
between the means is real or it can be attributed to sampling variability. 
ANALYSIS OF VARIANCE (ANOVA) 
Many situations involve collecting data on three or more group of individuals, with the 
objective of determining whether any true differences in mean performance exist among the 
conditions under the study. This often happens in experimental situations where several 
different treatments may be under comparison. In the above situation, ANOVA is a way to 
test the equality of three or more means of more than two groups. 
POST HOC ANALYSIS-TUKEY’S TEST 
It consists of statistical analyses that were not specified before the data was seen. This 
typically creates a multiple testing problem because each potential analysis is effectively a 
statistical test. Multiple testing procedures are sometimes used to compensate, but that is 
often difficult or impossible to do precisely.  
Tukey’s test is used as a sequel to a significant analysis of variance test, to determine which 
of several groups are actually significantly different from one another. It has built-in 
protection against an increased risk of a type I error. 
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RESULTS 
1. GINGIVAL BLEEDING INDEX 
Intragroup comparison  
Group I: The mean GBI at baseline was 11.32±2.08 
Group II: The mean GBI at baseline was 81.36±6.29 and at 3 months was 
23.97±3.86. The mean reduction in GBI from baseline to 3 months was statistically 
significant (p=0.000).  
Group III: The mean GBI at baseline was 78.19±5.01 and at 3 months was 
19.32±2.89. The mean reduction in GBI from baseline to 3 months was statistically 
significant (p=0.000).  
Intergroup comparison  
ANOVA comparing the mean baseline values among group I, group II and group III 
gave an F value of 1020.67 which was statistically significant(p=0.000). 
POST HOC analysis for multiple comparisons of baseline GBI between group I and 
II, group I and III was statistically significant(p=0.000) and group II and III was not 
statistically significant(p=0.178) 
Independent t tests to compare the mean 3 month values of PPD of group II and III 
gave a t value of 3.72 and was statistically significant(p=0.001) 
2. PLAQUE INDEX  
Intragroup comparison  
Group I: The mean plaque index score at baseline was 0.71±0.12 
Group II: The mean plaque index score at baseline was 2.66±0.21 and at 3 months 
was 0.85±0.21. The mean difference in plaque score from baseline to 3 month was 
statistically significant (p=0.000).  
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Group III: The mean plaque index score at baseline was 2.12±0.32 and at 3 months 
was 0.74±0.21. The mean reduction in plaque score from baseline to 3 months was 
statistically significant (p=0.000).  
Intergroup comparison  
ANOVA comparing the mean baseline values among group I, group II and group III 
gave an F value of 1821.9 which was statistically significant(p=0.000). 
POST HOC analysis for multiple comparisons of baseline PI between group I and II, 
group I and III, group II and III was statistically significant(p=0.000) 
Independent t tests to compare the mean 3 month values of PI of group II and III gave 
a t value of 1.43 and was not statistically significant(p=0.165) 
3. PROBING POCKET DEPTH  
Intragroup comparison  
Group I: The mean PPD at baseline was 2.18±0.36 
Group II: The mean PPD at baseline was 6.79 ±0.42 and at 3 months was 3.86±0.48. 
The mean reduction in PPD from baseline to 3 months was statistically significant 
(p=0.000).  
Group III: The mean PPD at baseline was 7.18±0.42 and at 3 months was 4.69±0.48. 
The mean reduction in PPD from baseline to 3 months was statistically significant 
(p=0.000).  
Intergroup comparison  
ANOVA comparing the mean baseline values among group I, group II and group III 
gave an F value of 731.1 which was statistically significant(p=0.000). 
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POST HOC analysis for multiple comparisons of baseline PPD between group I and 
II, group I and III was statistically significant(p=0.000) and group II and III was 
statistically significant(p=0.029) 
Independent t tests to compare the mean 3 month values of PPD of group II and III 
gave a t value of 4.77 and was statistically significant(p=0.000) 
4. CLINICAL ATTACHMENT LEVEL  
Intragroup comparison  
Group I: The mean CAL at baseline was 0.000 
Group II: The mean CAL at baseline was 6.79±0.45 and at 3 months was 3.89±0.48. 
The mean reduction in CAL from baseline to 3 months was statistically significant 
(p=0.000).  
Group III: The mean CAL at baseline was 7.14±0.42 and at 3 months was 4.69±0.42. 
The mean reduction in CAL from baseline to 3 months was statistically significant 
(p=0.000).  
Intergroup comparison  
ANOVA comparing the mean baseline values among group I, group II and group III 
gave an F value of 1945.37 which was statistically significant(p=0.000). 
POST HOC analysis for multiple comparisons of baseline CAL between group I and 
II, group I and III was statistically significant(p=0.000) and group II and III was 
statistically significant(p=0.023) 
Independent t tests to compare the mean 3 month values of CAL of group II and III 
gave a t value of 4.88 and was statistically significant(p=0.000) 
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5. SERUM INTERLEUKIN-6 LEVEL 
Intragroup comparison  
Group I: The mean serum IL-6 level at baseline was 13.99±1.24 
Group II: The mean serum IL-6 level at baseline was 18.65±2.84 and at 3 months was 
13.87±1.21. The mean reduction in serum IL-6 level from baseline to 3 months was 
statistically significant (p=0.000).  
Group III: The mean serum IL-6 level at baseline was 17.67±1.07 and at 3 months 
was 13.41±0.79. The mean reduction in IL-6 level from baseline to 3 months was 
statistically significant (p=0.000).  
Intergroup comparison  
ANOVA comparing the mean baseline values among group I, group II and group III 
gave an F value of 25.26 which was statistically significant(p=0.000). 
POST HOC analysis for multiple comparisons of baseline serum IL-6 level between 
group I and II, group I and III was statistically significant(p=0.000) and group II and 
III was not statistically significant(p=0.341) 
Independent t tests to compare the mean 3 month values of serum IL-6 levels of 
group II and III gave a t value of 1.24 and was not statistically significant(p=0.225) 
6. SERUM HEPCIDIN LEVEL 
Intragroup comparison  
Group I: The mean serum Hepcidin level at baseline was 60.54±2.15 
Group II: The mean serum Hepcidin level at baseline was 68.04±2.99 and at 3 
months was 61.49±2.41. The mean reduction in serum Hepcidin level from baseline 
to 3 months was statistically significant (p=0.000).  
Results 
 
52 
 
Group III: The mean serum Hepcidin level at baseline was 65.79±1.79 and at 3 
months was 60.42±1.99. The mean reduction in serum Hepcidin level from baseline 
to 3 months was statistically significant (p=0.000).  
Intergroup comparison  
ANOVA comparing the mean baseline values among group I, group II and group III 
gave an F value of 39.64 which was statistically significant(p=0.000). 
POST HOC analysis for multiple comparisons of baseline serum Hepcidin levels 
between group I and II, group I and III was statistically significant(p=0.000) and 
group II and III wasstatistically significant(p=0.034) 
Independent t tests to compare the mean 3 month values of serum Hepcidin levels of 
group II and III gave a t value of 1.33 and was not statistically significant(p=0.193) 
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Table 1: MASTER CHART 1-GROUP-I (CONTROL GROUP)-HEALTHY SUBJECTS 
[GBI-Gingival Bleeding Index, PPD-Probing Pocket Depth, CAL-Clinical Attachment Level, PI-Plaque Index] 
 
S.NO AGE SEX 
GBI (%) PPD (mm) CAL (mm) PI 
SERUM IL-6 
(pg ml-1 ) 
SERUM HEPCIDIN 
(ng ml-1) 
BL BL BL BL BL BL 
1. 45 F 8.69 2.02 0 0.61 12.8 60.7 
2. 45 M 9.02 2.52 0 0.53 15.2 61.2 
3. 55 M 11.52 2.71 0 0.83 12.5 61.5 
4. 47 M 8.78 2.63 0 0.79 14.7 54.4 
5. 40 M 12.11 1.88 0 0.89 12.2 60.2 
6. 43 M 9.92 2.17 0 0.58 14.5 60.5 
7. 35 F 14.08 1.54 0 0.67 14.4 61.8 
8. 42 F 8.52 1.9 0 0.59 13.7 64.2 
9. 48 F 13.61 2.43 0 0.72 17.2 60.1 
10. 34 M 10.32 2.13 0 0.68 14.1 60.8 
11. 49 F 11.86 2.26 0 0.81 13.8 61.4 
12. 50 F 12.54 2.39 0 0.86 14.5 58.3 
13. 30 F 13.36 2.49 0 0.58 12.9 60.7 
14. 24 M 14.76 1.74 0 0.76 13.7 59.8 
15. 31 M 10.84 1.81 0 0.64 13.6 62.5 
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Table 2:  MASTER CHART 2-GROUP-II (STUDY GROUP)-CHRONIC PERIODONTITIS PATIENTS AT BASELINE AND 3  
MONTHS AFTER PHASE I THERAPY 
[GBI-Gingival Bleeding Index, PPD-Probing Pocket Depth, CAL-Clinical Attachment Level, PI-Plaque Index] 
 
S.NO AGE SEX 
GBI (%) PPD (mm) CAL (mm) PI 
SERUM IL-6 
(pg ml-1) 
SERUM HEPCIDIN 
(ng ml-1) 
BL 
3M 
BL 
3M 
BL 
3M 
BL 
3M 
BL 
3M 
BL 
3M 
1. 50 F 
75.22 
17.53 
6.23 
3.43 
6.12 
3.36 
2.45 
0.93 
22.7 
16.2 
75.5 
65.9 
2. 40 M 
90.56 
24.53 
5.97 
3.65 
6.07 
3.73 
2.59 
0.85 
21.8 
12.9 
70.1 
65.4 
3. 51 M 
86.83 
28.61 
6.66 
4.32 
6.45 
4.29 
2.38 
1.09 
21.1 
15.8 
69.8 
60.7 
4. 46 M 
82.43 
21.73 
6.87 
4.26 
6.76 
4.19 
2.76 
1.12 
16.7 
13.3 
65.4 
60.3 
5. 43 F 
80.24 
26.96 
7.02 
3.53 
7.12 
3.61 
2.97 
0.74 
18.8 
14.1 
66.5 
59.1 
6. 34 F 
90.23 
18.77 
7.54 
2.99 
7.43 
2.84 
2.53 
0.58 
16.4 
12.8 
65.8 
58.5 
7. 50 M 
72.34 
19.74 
6.76 
3.65 
6.81 
3.73 
2.61 
0.73 
16.2 
12.1 
71.3 
64.8 
8. 44 F 
80.37 
19.44 
7.21 
4.21 
7.34 
4.27 
2.28 
0.59 
16.8 
13.2 
65.4 
60.2 
9. 40 F 
85.57 
23.82 
6.98 
3.63 
7.08 
3.83 
2.73 
1.18 
21.9 
14.3 
70.2 
62.4 
10. 41 M 
89.21 
27.63 
6.59 
3.63 
6.63 
3.69 
2.55 
0.97 
24.2 
14.5 
66.3 
61.9 
11. 45 M 
75.55 
28.91 
6.37 
4.23 
6.24 
4.16 
2.74 
0.63 
16.1 
12.8 
69.8 
63.5 
12. 49 F 
70.98 
27.45 
7.31 
4.74 
7.35 
4.76 
2.89 
0.83 
16.8 
12.5 
68.1 
60.4 
13. 35 F 
78.93 
23.64 
6.51 
4.38 
6.56 
4.41 
2.91 
1.06 
17.1 
14.9 
65.3 
58.8 
14. 37 M 
83.29 
22.76 
6.81 
3.36 
6.65 
3.43 
2.76 
0.57 
16.6 
14.4 
65.4 
60.1 
15. 42 F 
78.65 
27.97 
6.99 
3.75 
7.17 
3.85 
2.82 
0.83 
16.5 
14.3 
65.7 
60.3 
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Table 3: MASTER CHART 3-GROUP-III (STUDY GROUP)-AGGRESSIVE PERIODONTITIS PATIENTS AT BASELINE AND 3 
MONTHS AFTER PHASE-I THERAPY 
[GBI-Gingival Bleeding Index, PPD-Probing Pocket Depth, CAL-Clinical Attachment Level, PI-Plaque Index] 
 
S.NO AGE SEX 
GBI (%) PPD (mm) CAL (mm) PI 
SERUM IL-6 
(pg ml-1) 
SERUM HEPCIDIN 
(ng ml-1) 
BL 3M BL 3M BL 3M BL 3M BL 3M BL 3M 
1. 26 F 75.26 23.91 6.94 4.96 6.83 4.89 1.72 0.53 17.6 13.8 63.8 60.6 
2. 22 F 72.16 21.83 7.97 5.02 7.99 5.17 1.83 0.64 18.9 13.4 64.7 61.2 
3. 21 M 72.52 19.31 6.71 4.73 6.83 4.82 2.57 0.79 16.4 12.3 64.3 58.3 
4. 37 M 83.63 17.34 7.08 4.91 7.02 4.85 2.31 0.84 16.8 13.8 66.8 57.9 
5. 36 F 81.45 15.52 7.53 5.18 7.47 5.12 1.92 0.81 17.9 13.4 67.1 60.7 
6. 25 F 80.29 15.94 7.92 5.21 7.88 5.16 1.79 1.03 20.1 14.9 64.8 58.6 
7. 22 F 77.69 16.82 7.46 4.86 7.32 4.72 1.88 0.69 16.8 12.7 63.9 57.3 
8. 18 F 87.51 23.65 6.85 4.41 6.64 4.35 2.39 0.51 16.7 12.6 68.2 63.5 
9. 23 F 79.52 22.72 6.99 4.47 6.82 4.33 2.33 0.94 18.4 14.1 70.1 63.7 
10. 26 M 81.41 20.71 6.53 3.94 6.61 4.04 2.46 0.82 17.5 12.6 65.3 59.9 
11. 30 M 78.75 19.98 6.81 4.09 6.92 4.13 2.52 0.51 16.8 12.9 65.8 60.6 
12. 19 M 70.17 19.54 7.27 5.15 7.15 5.09 2.41 0.66 16.5 13.4 64.4 58.6 
13. 30 F 73.63 15.61 7.25 5.06 7.21 5.01 1.79 1.18 18.5 14.1 67.3 62.7 
14. 24 M 83.96 16.73 6.93 3.68 7.02 3.97 1.84 0.55 18.7 12.7 65.9 61.5 
15. 28 F 74.84 20.15 7.38 4.57 7.42 4.62 1.96 0.61 17.4 14.5 64.5 61.1 
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Table 4: DESCRIPTIVE STATISTICS OF GROUP-I 
 N Minimum Maximum Mean Std. 
Deviation 
Statistic Statistic Statistic Statistic Std. 
Error 
Statistic 
GROUP 1 AGE 15 24 55 41.20 2.245 8.695 
GROUP 1 GBI 15 8.52 14.76 11.3287 .53891 2.08718 
GROUP 1 PPD 15 1.54 2.71 2.1747 .09114 .35298 
GROUP 1 CAL 15 .00 .00 .0000 .00000 .00000 
GROUP 1 PI 15 .53 .89 .7027 .02972 .11511 
GROUP 1 SERUM IL6 15 12.20 17.20 13.9867 .31891 1.23512 
GROUP 1 SERUM HEPCIDIN 15 54.40 64.20 60.5400 .55470 2.14835 
[GBI-Gingival Bleeding Index, PPD-Probing Pocket Depth, CAL-Clinical Attachment Level, PI-plaque Index] 
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Table 5: DESCRIPTIVE STATISTICS OF GROUP-II 
 N Minimum Maximum Mean Std. Deviation 
Statistic Statistic Statistic Statistic Std. Error Statistic 
GROUP 2 AGE 15 34 51 43.13 1.407 5.449 
GROUP 2 GBI BL 15 70.98 90.56 81.3600 1.62349 6.28773 
GROUP 2 GBI 3M 15 17.53 28.91 23.9660 1.00055 3.87513 
GROUP 2 PPD BL 15 5.97 7.54 6.7880 .10787 .41779 
GROUP 2 PPD 3M 15 2.99 4.74 3.8507 .12308 .47669 
GROUP 2 CAL BL 15 6.07 7.43 6.7853 .11645 .45100 
GROUP 2 CAL 3M 15 2.84 4.76 3.8767 .12463 .48268 
GROUP 2 PI BL 15 2.28 2.97 2.6647 .05216 .20202 
GROUP 2 PI 3M 15 .57 1.18 .8467 .05340 .20680 
GROUP 2 SERUM IL6 BL 15 16.10 24.20 18.6467 .73406 2.84300 
GROUP 2 SERUM IL6 3M 15 12.10 16.20 13.8733 .31114 1.20503 
GROUP 2 SERUM HEPCIDIN BL 15 65.30 75.50 68.0400 .77366 2.99638 
GROUP 2 SERUM HEPCIDIN 3M 15 58.50 65.90 61.4867 .62051 2.40323 
[GBI-Gingival Bleeding Index, PPD-Probing Pocket Depth, CAL-Clinical Attachment Level, PI-plaque Index] 
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 Table 6: DESCRIPTIVE STATISTICS OF GROUP-III  
 N Minimum Maximum Mean Std. Deviation 
Statistic Statistic Statistic Statistic Std. Error Statistic 
GROUP 3 AGE 15 18 37 25.80 1.448 5.609 
GROUP 3 GBI BL 15 70.17 87.51 78.1860 1.29269 5.00656 
GROUP 3 GBI 3M 15 15.52 23.91 19.3173 .74734 2.89444 
GROUP 3 PPD BL 15 6.53 7.97 7.1747 .10868 .42093 
GROUP 3 PPD 3M 15 3.68 5.21 4.6827 .12349 .47829 
GROUP 3 CAL BL 15 6.61 7.99 7.1420 .10685 .41382 
GROUP 3 CAL 3M 15 3.97 5.17 4.6847 .10881 .42141 
GROUP 3 PI BL 15 1.72 2.57 2.1147 .08102 .31378 
GROUP 3 PI 3M 15 .51 1.18 .7407 .05179 .20059 
GROUP 3 SERUM IL6 BL 15 16.40 20.10 17.6667 .27649 1.07083 
GROUP 3 SERUM IL6 3M 15 12.30 14.90 13.4133 .20092 .77815 
GROUP 3 SERUM HEPCIDIN BL 15 63.80 70.10 65.7933 .46378 1.79621 
GROUP 3 SERUM HEPCIDIN 3M 15 57.30 63.70 60.4133 .51315 1.98741 
[GBI-Gingival Bleeding Index, PPD-Probing Pocket Depth, CAL-Clinical Attachment Level, PI-plaque Index] 
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Table 7: PAIRED t TEST TO COMPARE THE MEAN VALUES BEFORE AND AFTER TREATMENT IN GROUP II 
 
Variables 
Paired Differences t df Sig. 
Mean Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence Interval 
of the Difference 
Lower Upper 
Pair 1 GROUP 2 GBI BL - 
GROUP 2 GBI 3M 
57.39400 7.27146 1.87748 53.36720 61.42080 30.570 14 .000* 
Pair 2 GROUP 2 PPD BL - 
GROUP 2 PPD 3M 
2.93733 .64095 .16549 2.58239 3.29228 17.749 14 .000* 
Pair 3 GROUP 2 CAL BL - 
GROUP 2 CAL 3M 
2.90867 .65531 .16920 2.54577 3.27156 17.191 14 .000* 
Pair 4 GROUP 2 PI BL - 
GROUP 2 PI 3M 
1.81800 .27439 .07085 1.66605 1.96995 25.661 14 .000* 
Pair 5 GROUP 2 SERUM IL6 
BL - GROUP 2 SERUM 
IL6 3M 
4.77333 2.38910 .61686 3.45029 6.09637 7.738 14 .000* 
Pair 6 GROUP 2 SERUM 
HEPCIDIN BL - GROUP 
2 SERUM HEPCIDIN 
3M 
6.55333 1.57882 .40765 5.67901 7.42765 16.076 14 .000* 
*The differences between the mean values of all the variables before and after treatment are statistically significant (p<0.05) 
[GBI-Gingival Bleeding Index, PPD-Probing Pocket Depth, CAL-Clinical Attachment Level, PI-plaque Index] 
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 Table 8: PAIRED t TEST TO COMPARE THE MEAN VALUES BEFORE AND AFTER TREATMENT IN GROUP III  
 
Variables 
Paired Differences T df Sig. 
Mean Std. 
Deviation 
Std. Error 
Mean 
95% Confidence Interval 
of the Difference 
Lower Upper 
Pair 1 GROUP 3 GBI BL - 
GROUP 3 GBI 3M 
58.86867 5.90988 1.52593 55.59588 62.14145 38.579 14 .000* 
Pair 2 GROUP 3 PPD BL - 
GROUP 3 PPD 3M 
2.49200 .36717 .09480 2.28867 2.69533 26.286 14 .000* 
Pair 3 GROUP 3 CAL BL - 
GROUP 3 CAL 3M 
2.45733 .34100 .08804 2.26850 2.64617 27.910 14 .000* 
Pair 4 GROUP 3 PI BL - 
GROUP 3 PI 3M 
1.37400 .39520 .10204 1.15515 1.59285 13.465 14 .000* 
Pair 5 GROUP 3 SERUM IL6 
BL - GROUP 3 SERUM 
IL6 3M 
4.25333 .89192 .23029 3.75940 4.74726 18.469 14 .000* 
Pair 6 GROUP 3 SERUM 
HEPCIDIN BL - 
GROUP 3 SERUM 
HEPCIDIN 3M 
5.38000 1.49914 .38708 4.54980 6.21020 13.899 14 .000* 
*The differences between the mean values of all the variables before and after treatment are statistically significant (p<0.05) 
[GBI-Gingival Bleeding Index, PPD-Probing Pocket Depth, CAL-Clinical Attachment Level, PI-plaque Index] 
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Table 9: ANOVA TO COMPARE THE MEAN BASELINE VALUES OF THE PARAMETERS AMONG GROUP I, GROUP II AND 
GROUP III 
Variables Sum of Squares df Mean Square F Sig. 
GBI Between Groups 46921.825 2 23460.912 1020.668 .000* 
Within Groups 965.405 42 22.986   
Total 47887.230 44    
PPD Between Groups 232.162 2 116.081 731.099 .000* 
Within Groups 6.669 42 .159   
Total 238.830 44    
CAL Between Groups 485.881 2 242.940 1945.370 .000* 
Within Groups 5.245 42 .125   
Total 491.126 44    
PI Between Groups 343.664 2 171.832 1821.860 .000* 
Within Groups 3.961 42 .094   
Total 347.625 44    
SERUM IL6 Between Groups 181.092 2 90.546 25.257 .000* 
Within Groups 150.568 42 3.585   
Total 331.660 44    
SERUM HEPCIDIN Between Groups 444.475 2 222.238 39.638 .000* 
Within Groups 235.481 42 5.607   
Total 679.956 44    
*The differences between the mean baseline values of all the variables among group 1, group 2 and group 3 are statistically significant (p<0.05) 
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Table 10: POST HOC ANALYSIS FOR MULTIPLE COMPARISONS OF BASELINE GBI 
 
 
VARIABLE 
 
GROUPS 
 
MEAN 
DIFFERENCE 
 
STD. 
ERROR 
 
SIG. 
 
95% CONFIDENCE INERVAL 
LOWER UPPER 
 
 
 
BASELINE GBI 
GROUP 1 GROUP 2 
70.03133 1.75065 .000* 65.7781 74.2845 
GROUP 3 
66.85733 1.75065 .000* 62.6041 71.1105 
GROUP 2 GROUP 1 
70.03133 1.75065 .000* 65.7781 74.2845 
GROUP 3 
3.17400 1.75065 .178 1.0792 7.4272 
GROUP 3 GRUOP 1 
66.85733 1.75065 .000* 62.6041 71.1105 
GROUP 2 
3.17400 1.75065 .178 1.0792 7.4272 
*The comparisons of baseline GBI are statistically significant (p<0.05) 
[GBI-Gingival Bleeding Index] 
 
 
Results-Tables 
 
63 
 
 
 
 
Table 11: POST HOC ANALYSIS FOR MULTIPLE COMPARISONS OF BASELINE PPD 
 
 
VARIABLE 
 
GROUPS 
 
MEAN 
DIFFERENCE 
 
STD. ERROR 
 
SIG. 
95% CONFIDENCE 
INERVAL 
LOWER UPPER 
 
 
 
BASELINE 
PPD 
GROUP 1 GROUP 2 
4.61333 .14550 .000* 4.2598 4.9668 
GROUP 3 
5.00000 .14550 .000* 4.6465 5.3535 
GROUP 2 GROUP 1 
4.61333 .14550 .000* 4.2598 4.9668 
GROUP 3 
.38667 .14550 .029* .0332 .7402 
GROUP 3 GRUOP 1 
5.00000 .14550 .000* 4.6465 5.3535 
GROUP 2 
.38667 .14550 .029* .0332 .7402 
*The comparisons of baseline PPD are statistically significant (p<0.05) 
[PPD-Probing Pocket Depth] 
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 Table 12: POST HOC ANALYSIS FOR MULTIPLE COMPARISONS OF BASELINE CAL  
 
 
VARIABLE 
 
GROUPS 
 
MEAN 
DIFFERENCE 
 
STD. 
ERROR 
 
SIG. 
95% CONFIDENCE 
INERVAL 
LOWER UPPER 
 
 
 
BASELINE CAL 
GROUP 1 GROUP 2 6.78533 .12904 .000* 6.4718 7.0988 
GROUP 3 7.14200 .12904 .000* 6.8285 7.4555 
GROUP 2 GROUP 1 6.78533 .12904 .000* 6.4718 7.0988 
GROUP 3 .35667 .12904 .023* .0432 .6702 
GROUP 3 GRUOP 1 7.14200 .12904 .000* 6.8285 7.4555 
GROUP 2 .35667 .12904 .023* .0432 .6702 
*The comparisons of baseline CAL are statistically significant (p<0.05) 
[CAL-Clinical Attachment Level] 
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Table 13: POST HOC ANALYSIS FOR MULTIPLE COMPARISONS OF BASELINE PI 
   
 
VARIABLE 
 
GROUPS 
 
MEAN 
DIFFERENCE 
 
STD. 
ERROR 
 
SIG. 
 
95% CONFIDENCE 
INERVAL 
LOWER UPPER 
 
 
 
BASELINE PI 
GROUP 1 GROUP 2 1.41200 .11214 .000* 1.1396 1.6844 
GROUP 3 6.43933 .11214 .000* 6.1669 6.7118 
GROUP 2 GROUP 1 1.41200 .11214 .000* 1.1396 1.6844 
GROUP 3 5.02733 .11214 .000* 4.7549 5.2998 
GROUP 3 GRUOP 1 6.43933 .11214 .000* 6.1669 6.7118 
GROUP 2 5.02733 .11214 .000* 4.7549 5.2998 
*The comparisons of baseline PI are statistically significant (p<0.05) 
[PI-Plaque Index] 
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Table 14: POST HOC ANALYSIS FOR MULTIPLE COMPARISONS OF BASELINE SERUM IL-6 
 
 
VARIABLE 
 
GROUPS 
 
MEAN 
DIFFERENCE 
 
STD. ERROR 
 
SIG. 
95% CONFIDENCE 
INERVAL 
LOWER UPPER 
 
 
 
BASELINE 
SERUM 
IL6 
GROUP 1 GROUP 2 4.66000 .69137 .000* 2.9803 6.3397 
GROUP 3 3.68000 .69137 .000* 2.0003 5.3597 
GROUP 2 GROUP 1 4.66000 .69137 .000* 2.9803 6.3397 
GROUP 3 .98000 .69137 .341 .6997 2.6597 
GROUP 3 GRUOP 1 3.68000 .69137 .000* 2.0003 5.3597 
GROUP 2 .98000 .69137 .341 .6997 2.6597 
*The comparisons of baseline serum IL-6 are statistically significant (p<0.05) 
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Table 15: POST HOC ANALYSIS FOR MULTIPLE COMPARISONS OF BASELINE SERUM HEPCIDIN 
 
 
VARIABLE 
 
GROUPS 
 
MEAN 
DIFFERENCE 
 
STD. ERROR 
 
SIG. 
95% CONFIDENCE 
INERVAL 
LOWER UPPER 
 
 
 
BASELINE 
SERUM 
HEPCIDIN 
GROUP I GROUP 2 7.50000 .86462 .000* 5.3994 9.6006 
GROUP 3 5.25333 .86462 .000* 3.1528 7.3539 
GROUP II GROUP 1 7.50000 .86462 .000* 5.3994 9.6006 
GROUP 3 2.24667 .86462 .034* .1461 4.3472 
GROUP 3 GRUOP 1 5.25333 .86462 .000* 3.1528 7.3539 
GROUP 2 2.24667 .86462 .034* .1461 4.3472 
*The comparisons of baseline serum Hepcidin are statistically significant (p<0.05) 
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Table 16: INDEPENDENT t TESTS TO COMPARE THE MEAN 3 MONTHS VALUES OF THE PARAMETERS OF GROUP II 
AND GROUP III 
 
 
 
Variables 
Independent t-test 
t Df Sig. Mean 
Difference 
Std. Error 
Difference 
95% Confidence Interval 
of the Difference 
Lower Upper 
GBI 3.722 28 .001* 4.64867 1.24885 2.09051 7.20682 
PPD 4.772 28 .000* .83200 .17436 1.18915 .47485 
CAL 4.884 28 .000* .80800 .16544 1.14689 .46911 
PI 1.425 28 .165 .10600 .07439 .04638 .25838 
 
SERUM IL6 
 
1.242 
 
28 
 
.225 
 
.46000 
 
.37037 
 
.29867 
 
1.21867 
SERUM HEPCIDIN  
1.333 
 
28 
 
.193 
 
1.07333 
 
.80521 
 
.57605 
 
2.72272 
*The differences between the mean 3 months values the variables of group II and group III are statistically significant (p<0.05) 
[GBI-Gingival Bleeding Index, PPD-Probing Pocket Depth, CAL-Clinical Attachment Level, PI-plaque Index] 
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[GBI-Gingival Bleeding Index] 
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DISCUSSION 
Periodontal disease is a multifactorial chronic inﬂammatory disease that leads to a 
host response resulting in inﬂammatory breakdown of tooth-supporting osseous and 
soft tissues, in response to a microbial challenge. Although the presence of microbial 
organisms is required as the primary etiologic agents for disease initiation in 
periodontitis, it is inadequate for progression and increased severity of disease. The 
onset, progression, and severity of periodontal disease are related to the interaction 
between periodontal microorganisms and the host immune response. In response to 
bacterial endotoxins, production of acute phase proteins which cause tissue 
breakdown occurs as a part of host response.109  
Substantial scientiﬁc data indicate that the localized infections characteristic of 
periodontitis can have a signiﬁcant effect on the systemic health of humans and 
animals.110 It has been proven that serum IL-6 levels are increased in periodontitis 
patients. This elevation of IL-6 can induce the hepatic expression of an acute phase 
protein called Hepcidin.  
Hepcidin was discovered in 2001 by Park et al and it is considered to play a key role 
in anaemia of inflammation. There are various studies showing that periodontal 
disease is associated with anaemia. It is hypothesized that elevation of serum 
Hepcidin and IL-6 can lead to anaemia in periodontitis patients. 
Anaemia is associated with enhanced oxidative stress. The shortage of iron causes 
tissue hypoxia and affects the production of iron-containing antioxidant proteins, 
which tilts the balance to the oxidative side111. In an anaemic state, a relative decrease 
in oxygen perfusion into the tissues has been suggested to act as an altering factor in 
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the response of the periodontium to local irritation leading to periodontal 
destruction112. The literature thus proves the two-way relationship between the 
periodontal disease and anaemia. 
Our study principally aims to, 
 Establish the relationship between periodontal disease and serum Hepcidin 
and IL-6 levels.  
 To evaluate the effectiveness of phase 1 periodontal therapy in reducing 
serum hepcidin and IL-6 levels. 
In the present study, 45 subjects were enrolled, out of which 15 were healthy subjects 
(Group I), 15 were generalised chronic periodontitis patients (Group II) and 15 were 
generalised aggressive periodontitis(Group III) patients. Both sexes were included in 
the study. 
Smokers, Patients with systemic diseases, Medically compromised patients such as 
uncontrolled diabetes, immunosuppression, bleeding disorders, cancer, stroke and 
severe osteoporosis, patients on iron replacement for treatment of anemia, patient 
who underwent periodontal treatment in the past 6 months, patients using NSAIDs 
and antibiotics within 3 months prior to the study, Pregnancy and lactation, Patients 
under bisphosphonates medication, Organ transplantation and auto-immune diseases 
were all excluded from the study. 
Less consideration has been given to explore the role of chronic oral diseases on 
systemic health until recently. The hypothesis that periodontal infection, may be a 
risk factor for important medical outcomes, represents a paradigm shift in thinking 
about the association between the oral and systemic condition. The subgingival 
microbiota in patients with periodontitis provides a significant and persistent gram-
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negative bacterial challenge to the host. Microbes and their products, have ready 
entree to the systemic circulation through the ulcerated/discontinuous sulcular 
epithelium/junctional epithelium found in periodontal diseases.113 It has therefore 
been speculated that periodontitis results in a low grade systemic inflammation. 
Anaemia of inflammation is a cytokine mediated anaemia. It is frequently seen in 
clinical practice and is characterized by hypoferramia with adequate 
reticuloendotelial iron stores, normal to elevated ferritin concentrations and it is a 
regular complication of chronic inflammatory conditions114,115. Hutteret al116 
suggested that periodontitis has chronic and systemic effects and that periodontitis 
may tend towards anaemia. A tendency toward development of anaemia in patients 
with chronic periodontitis had been previously reported in various studies117,118,119. 
The expression of Interleukin-6 and Hepcidin during inflammation is thought to be 
the main reason for development of anaemia of chronic disease. 
Vilela et al in 2011, found that treatment of chronic periodontitis decreases serum 
prohepcidin levels in patients with chronic kidney disease. 
Carvalho et al in 2015 in his study found that both serum Interleukin-6 and Hepcidin 
levels were increased in chronic periodontitis patients. This was the first study to 
evaluate the Hepcidin levels in chronic periodontitis patients. 
Lin-Na Guo in 2018 found that Serum ferritin and hepcidin levels in the Chronic 
periodontitis and Chronic periodontitis with Type2 diabetes mellitus groups were 
higher than in the control group. 
Till now, there are no studies evaluating the Hepcidin levels in aggressive 
periodontitis patients and for evaluation of effectiveness of Phase 1 therapy in 
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reducing serum hepcidin levels in chronic and aggressive periodontitis patients. This 
provides the rationale for our study. 
In our study, the baseline values of Interleukin-6 and Hepcidin levels in healthy 
subjects and chronic periodontitis patients were 13.99±1.24, 60.54±2.15 and 
18.65±2.84, 68.04±2.99 respectively. The levels of IL-6 and Hepcidin were elevated 
in chronic periodontitis patients when compared with healthy subjects, which co-
related with the results of the study from Carvalho et al 2015.  
In aggressive periodontitis patients the values were, 17.67±1.07, 65.79±1.79 for 
Interleukin-6 and Hepcidin respectively which was found to be elevated when 
compared with healthy subjects. 
ANOVA was used to compare the mean baseline values of all the 
parameters(GBI,PPD,PI,IL-6,Hepcidin) among groups I,II and III, which showed that 
the differences between the mean baseline values of all the parameters among group 
I,II and III were statistically significant(p<0.05) 
In Group II, the mean GBI at baseline was 81.36±6.29 and at 3 months was 
23.97±3.86. The mean reduction in GBI from baseline to 3 months was statistically 
significant (p=0.000). The mean plaque index score at baseline was 2.66±0.21 and at 
3 months was 0.85±0.21. The mean difference in plaque score from baseline to 3 
month was statistically significant (p=0.000). The mean PPD at baseline was 6.79 
±0.42 and at 3 months was 3.86±0.48. The mean reduction in PPD from baseline to 3 
months was statistically significant (p=0.000). 
In group III, The mean GBI at baseline was 78.19±5.01 and at 3 months was 
19.32±2.89. The mean reduction in GBI from baseline to 3 months was statistically 
significant (p=0.000). The mean plaque index score at baseline was 2.12±0.32 and at 
3 months was 0.74±0.21. The mean reduction in plaque score from baseline to 3 
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months was statistically significant (p=0.000). The mean PPD at baseline was 
7.18±0.42 and at 3 months was 4.69±0.48. The mean reduction in PPD from baseline 
to 3 months was statistically significant (p=0.000). 
In both Group II and III, Gingival Bleeding Index, Plaque index and pocket probing 
depth reduced after 3 months following phase I therapy. This shows the efficiency of 
non-surgical therapy in improving periodontal health (vilela et al 2011, Pradeep et 
al 2011).  
In group II, the mean serum Hepcidin level at baseline was 68.04±2.99 and at 3 
months after phase I therapy was 61.49±2.41. The mean reduction in serum Hepcidin 
level from baseline to 3 months was statistically significant (p=0.000). This was 
similar to reports by Guo et al 2018, who reported that hepcidin levels reduced in 
chronic periodontitis patients after phase I therapy. The mean serum IL-6 level at 
baseline was 18.65±2.84 and at 3 months was 13.87±1.21. The mean reduction in 
serum IL-6 level from baseline to 3 months was statistically significant (p=0.000) 
which co-related with previous studies on IL-6 levels in chronic periodontitis patients 
after Phase I therapy by Marcaccini AM 2009, Nakajima T 2010 etc. 
In group III, the mean serum Hepcidin level at baseline was 65.79±1.79 and at 3 
months was 60.42±1.99. The mean reduction in serum Hepcidin level from baseline 
to 3 months was statistically significant (p=0.000). The mean serum IL-6 level at 
baseline was 17.67±1.07 and at 3 months was 13.41±0.79. The mean reduction in IL-
6 level from baseline to 3 months was statistically significant (p=0.000).  
Ide et al 2003 reported that there was no statistically significant reduction in systemic 
inflammatory markers following periodontal therapy. However, Behle et al 2009 
reported that periodontal therapy resulted in overall reduction of various systemic 
inflammatory markers. In our study, we could positively correlate the levels of IL-6 
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and Hepcidin with periodontal disease status. The levels reduced following 
improvement in periodontal health in both group II and III. There was no statistically 
significant changes when comparing the mean 3 months values of IL-6 and Hepcidin 
of group II and III (p=0.225 and 0.193 respectively). 
When compared with healthy subjects the levels of IL-6 and Hepcidin in aggressive 
periodontitis patients were elevated as in chronic periodontitis patients. The IL-6 and 
Hepcidin levels at baseline and at 3 months after Phase I therapy in Aggressive 
periodontitis patients were slightly less than in chronic periodontitis patients but the 
difference was not statistically significant. The response to periodontal phase I 
therapy in both the groups were similar.  
This is the first study to evaluate the Hepcidin levels in aggressive periodontitis 
patients. Since IL-6 and Hepcidin are key regulators in development of anaemia of 
chronic disease. It is important to evaluate the relationship between periodontal 
disease and IL-6, Hepcidin levels. 
It is a well-established fact that periodontal disease is associated with anaemia 
(Anand et al 2014,Gokhale et al 2010) and elevated serum IL-6 levels (Geivelis et 
al, 1993; Costa et al, 2010; Shimada et al, 2010). The systemic levels of IL-6 seem 
to be affected by periodontal treatment, with an increase associated to the short-term 
inﬂammatory response to therapy (D’Aiuto et al, 2005; Tonetti et al, 2007) and 
long-term reductions when a clinical improvement in the periodontal status is 
obtained (D’Aiuto et al, 2004a; Marcaccini et al, 2009; Shimada et al, 2010). But 
there are limited studies regarding Hepcidin levels in periodontitis patients and its 
response to periodontal phase I therapy. Our study investigated the serum IL-6 and 
hepcidin levels in chronic and aggressive periodontitis patients and compared it with 
healthy subjects. The changes in levels after Phase I therapy in both groups were also 
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evaluated. It was shown that periodontal phase I therapy improved the periodontal 
health and reduced IL-6 and hepcidin levels in both groups. This reduction in serum 
hepcidin and IL-6 levels will help in improving the systemic status of the patient and 
reduces the chances for development of anaemia due to periodontal disease. Future 
studies with a larger sample size are necessary to further establish the association 
between Hepcidin and periodontal disease. 
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SUMMARY AND CONCLUSION 
Periodontal disease is a multifactorial inflammatory disease fundamentally initiated 
by chronic bacterial infection. In response to bacterial challenge the host produces 
various cytokines systemically. One of such cytokine is IL-6. Serum IL-6 level is 
found to be elevated in periodontitis patients. This elevation of Serum IL-6 levels can 
lead to increased production of an acute phase protein called Hepcidin by the liver. 
Hepcidin is considered the key regulator of anaemia of inflammation. It is speculated 
that increased levels of hepcidin and IL-6 in periodontal disease can cause anaemia. 
Anaemia causes oxidative stress and reduced oxygen perfusion in periodontal 
disease, leading to periodontal destruction. This proves the two-way relationship 
between anaemia and periodontal disease. All the above facts necessitates the need to 
explore the relationship between periodontal disease and anaemia. 
The present study was conducted, 
 To measure serum hepcidin and interleukin-6 levels in healthy subjects.  
 To measure serum hepcidin and interleukin-6 levels in patients with chronic 
periodontitis.  
 To measure serum hepcidin and interleukin-6 levels in patients with 
aggressive periodontitis.  
 To compare serum hepcidin and interleukin-6 levels in individuals with 
healthy periodontium (control group) and chronic periodontitis(study group) 
and aggressive periodontitis(study group)  
 To measure and compare serum hepcidin and interleukin-6 levels before and 
after phase I periodontal therapy in patients with chronic periodontitis.  
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 To measure and compare serum hepcidin and interleukin-6 levels before and 
after phase I periodontal therapy in patients with aggressive periodontitis.  
 To compare the serum IL-6 and hepcidin levels between chronic and 
aggressive periodontitis patients. 
A total of 45 patients were selected and divided into three groups of 15 each. Group I 
consisted of healthy subjects, Group II consisted of generalised chronic periodontitis 
patients, Group III consisted of generalised aggressive periodontitis patients. The 
clinical parameters and IL-6, Hepcidin levels were evaluated at baseline in group I, at 
baseline and 3 months after phase I therapy in group II and III. The values obtained 
were subjected to statistical analysis. 
The following observations were made from our study: 
 The IL-6 and Hepcidin levels were elevated in patients with chronic 
periodontitis when compared with healthy subjects. 
 The IL-6 and Hepcidin levels were elevated in patients with aggressive 
periodontitis when compared with healthy subjects.  
 The levels of IL-6 and hepcidin showed a considerable reduction 3 months 
after phase I therapy in both Groups. 
 There was no statistically significant difference in IL-6 and Hepcidin levels at 
both baseline and 3 months after phase I therapy between chronic and 
aggressive periodontitis patients. 
 All the clinical parameters showed a considerable improvement after phase I 
therapy in both Group II and III, and we can positively correlate the IL-6 and 
Hepcidin levels with the improvement in clinical parameters. 
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From the above outcomes, we could conclude that increased serum IL-6 and hepcidin 
levels are associated with both chronic and aggressive periodontitis patients. This 
elevation of serum hepcidin and IL-6 increases the risk for the development of 
anemia of chronic disease. In an anemic state, a relative decrease in oxygen perfusion 
into the tissues has been suggested to act as a modifying factor in the response of the 
periodontium to local irritation leading to periodontal destruction.  
Following phase I therapy the levels of IL-6 and hepcidin levels were reduced in both 
chronic and aggressive periodontitis patients. The Phase-I therapy in the treatment 
plan of periodontal disease including both chronic and aggressive periodontitis 
patients proves to Improve the systemic status of the patient by preventing the 
development of anaemia due to periodontal disease. 
In future, studies with a larger sample size may be employed, 
1) To further establish the association between serum Hepcidin levels and 
periodontal status of the patient  
2) To explore the association of serum IL-6 and Hepcidin levels in progression 
of periodontal disease. 
3) To evaluate the efficiency of phase I therapy in reducing serum IL-6 and 
Hepcidin levels. 
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Annexure-1 
PARTICIPANT INFORMATION SHEET 
TITLE OF THE STUDY: 
“A Comparative evaluation of Serum Hepcidin and interleukin-6 levels before 
and after phase I periodontal therapy in patients with chronic and aggressive 
periodontitis”  
NAME OF THE RESEARCH INSTITUTION: 
Tamil Nadu Government Dental College and Hospital, Chennai. 
PURPOSE OF THE STUDY: 
The purpose of this study is to compare Serum hepcidin and interleukin-6 levels in 
patients with chronic and aggressive periodontitis before and after phase-I 
periodontal therapy. 
PROCEDURE: 
 Case history will be taken, Intra Oral examination will be done, 
routine blood investigations will be done and X rays will be taken.  
 About half-tea spoon(2ml) of blood will be drawn from your hand 
before starting the non-surgical treatment and it will be sent for 
estimation of serum hepcidin and interleukin-6 levels. 
 Gums and deposits over the tooth will be examined. 
 Cleaning of the tooth will be done under local anaesthesia. 
 Then the blood sample(2ml-half tea spoon) will be collected again 3 
months after the non-surgical treatment and it will be sent for 
estimation of serum hepcidin and interleukin-6 levels. 
 
RISK OF PARTICIPATION: 
 Radiation exposure during Intraoral periapical view radiographic 
procedure.  
 Pain and discomfort due to treatment. 
 Pain and swelling during blood sample collection and local anaesthetic 
injection. This will be informed to the patients and necessary 
precautions will be taken.  
PROTECTION AND SAFETY MEASURES: 
- Lead apron and thyroid collars will be used while taking 
radiographs. 
- All instruments will be of standard quality and sterile.  
- Analgesics will be prescribed after treatment if necessary. 
BENEFITS OF PARTICIPATION: 
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Patient motivation and awareness regarding periodontal disease and its 
systemic effect. Scaling and root planing will be done for improvement of 
periodontal health. 
 
 
CONFIDENTIALITY: 
The identity of the patients participating in the research will be kept 
confidential throughout the study. In the event of any publication and 
presentation resulting from the research, no personally identifiable 
information will be shared. 
PARTICIPANTS RIGHTS: 
Taking part in the study is voluntary. You are free to decide whether to 
participate in the study or to withdraw at any time. Your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
COMPENSATION :  Nil 
 
 
 
 
____________________________________           _________________________ 
Name of the participant    Signature of the participant 
 
For queries related to study:               For queries related to rights of participant: 
Dr.S.Aiswarya,                     Dr.B.Saravanan,MDS 
PG student,                                                                          The Chairperson, 
Department of Periodontics,                                Institutional Ethical Committee, 
Tamil Nadu Government Dental College           Tamil Nadu Government Dental  
And Hospital,                                                                   College and Hospital, 
Chennai-600003.                                                                  Chennai-600003.         
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Annexure 2 
 
 
ஆராய்சச்ி பற்றிய தகவல் படிவம் 
ஆராய்சச்ிமமற்ககாள்பவர:்             மருதத்ுவர.்ஸ்ரீ.ஐஸ்வரய்ா 
வழிநடத்துபவர:்                                            மருதத்வர.்மமேஷ்வரிஇராமேந்திரன் 
 
ஆராய்சச்ியின் தலலப்பு: 
“நாட்பட்ட ஈறுஅழற்சிமநாய் மற்றும் தீவிர ஈறுஅழற்சிமநாய் 
உள்ளவரக்ளின் இரத்தத்தில் ேப்சிடின் மற்றும் இன்டரல்ூகின்-6 அளலவ 
அறுலவசிகிசல்சயில்லா ஈறுமருத்துவதத்ிற்கு முன்பும் பின்பும் ஒப்பிடட்ு 
மதிப்பீடு கசய்தல்" 
கசய்முலற: 
கீழ்கண்ட ஆய்வுகள்/பரிமசாதலனகள் உங்களுக்கு கசய்யப்படும்: 
 வாய் பரிமசாதலன - உட்புறம், கவளிப்பறம். 
 மநாயுற்ற பகுதியின் ஊடுகதிரப்டம் எடுக்கப்படும். 
 வழக்கமான இரத்தப்பரிமசாதலனகசய்யப்படும். 
 சிகிசல்சக்கு முன்பும் சிகிசல்சக்கு 3 மாதங்களுக்கு பின்பும் 
உங்கள் லகயிலிருந்து பரிமசாதலனக்காக 2மிலி (1/2 மதக்கரண்டி) 
அளவு இரத்தம் எடுக்கப்படும். 
 ஒவ்வாலம ஏற்படுகிறதா என்பலத கதரிந்துககாள்ள 0.5 மில்லி 
மரத்து மபாகும் மருந்து உங்களின் லகயில் பரிமசாதலனக்காக 
கசலுதத்ப்படும். பின்பு மநாயுற்ற பகுதியில் இம்மருந்து 
கசலுதத்ப்படும். 
  அல்ட்ரா மசானிக் கருவி மற்றும் லகக்கருவிகள் பயன்படுதத்ி பல் 
மற்றும் பல்லின் மவர ்சுத்தம் கசய்யப்படும். உப்புநீர ்ககாண்டு 
மநாயுற்ற பகுதி சுதத்ம் கசய்யப்படும். 
பங்மகற்பதினால் வரக்கூடிய பக்கவிலளவுகள்: 
 ஊடுகதிர ்படம் எடுக்கும் கபாழுது கதிரவ்ீசச்ினால் பாதிப்பு ஏற்பட 
வாய்ப்பு உள்ளது. 
 சிகிசல்சக்குப்பின் வலி ஏற்பட வாய்ப்பு உள்ளது. 
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 இரத்தம் எடுக்கும்கபாழுதும் மரத்து மபாகும் ஊசி கசலுதத்ும் 
கபாழுதும் வலி மற்றும் வீக்கம் வர வாய்ப்பு உள்ளது. 
பக்க விலளவுகள் ஏற்படாமல் தடுக்க உரிய முலறகள் பின்பற்றப்படும். 
பக்க விலளவுகள் ஏற்படாமல் தடுக்க பின்பற்றப்படும் முலறகள்: 
 ஊடுகதிர ் படம் எடுக்கப்படும் கபாழுது கலடஏ்ப்ரன், 
லதராய்டு காலர ்மபான்ற பாதுகாப்பு உபகரணங்கள் 
பயன்படுதத்ப்படும். 
 சிறந்த தரம் மற்றும் சுத்தமான கருவிகள் 
பயன்படுதத்ப்படும். 
 மதலவப்பட்டால் சிகிக்லசக்குப்பின் வலி நிவாரணி 
மருந்துகள் வழங்கப்படும். 
 
பங்மகற்பதினால் விலளயும் நன்லமகள்: 
 ஈறு அழற்சி மநாயினால் ஏற்படும் தீலமகலளப்பற்றி 
மநாயாளிகளுக்கு விழிப்புணரவ்ு ஏற்படுதத்ப்படும். 
 ஈறு அழற்சி மநாய்க்கு சிகிசல்ச அளிக்கப்படும். 
 
இரகசியகாப்பு: 
உங்கலள பற்றிய குறிப்புகள் பிறர ்அறியாவண்ணம் ஆராய்சச்ி 
முடியும்வலர இரகசியமாக பாதுகாக்கப்படும். அலதகவளிப்படுதத்ும் 
மநரங்களிள் எந்த தனிநபர ் அலடயாளங்களும் கவளிப்பட வாய்ப்பு 
கிலடயாது. 
 
தன்னாரவ்பங்மகற்பு: 
இந்த ஆராய்சச்ியில்  பங்கு கபறுவது தங்களின் தனிப்பட்ட முடிவு மற்றும் 
இந்த ஆராய்சச்ியிலிருந்து தாங்கள் எப்கபாழுது மவண்டுமானாலும் 
விலகிக்ககாள்ளலாம். தங்களின் இந்த திடீர ்முடிவு தங்களுக்மகா அல்லது 
ஆராய்சச்ியாளருக்மகா எவ்வித பாதிப்பும் ஏற்படுதத்ாது என்பலத 
கதரிவித்துக்ககாள்கிமறாம். 
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         _______________________                                                    _______________________ 
 மநாயாளியின் கபயர ்   மநாயாளியின் லககயாப்பம் 
 
______________________________________________________________________________ 
ஆராய்சச்ி த ாடர்புடடய                                                           பங்கேற்பாளரின் உரிடை 
த ாடர்புடடய ேவல்ேளுே்கு:                                                                                ேவல்ேளுே்கு: 
மருத்துவர.்ஸ்ரீ.ஐஸ்வரய்ா,                  மருத்துவர.்பி.சரவணனன், 
முதுகலல மாணவர,்                                                                                                 தலலவர,் 
தமிழ்நாடு அரசு பல் மருத்துவமலன                                                       நிறுவன கநறிமுலறகள் குழு, 
மற்றும் கல்லூரி,  கசன்லன-600003.                                                          தமிழ்நாடு அரசு பல் மருத்துவமலன 
                                                                                                                                                        மற்றும் கல்லூரி,  கசன்லன-600003.                                                                                                       
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Annexure 3:  
INFORMED CONSENT FORM 
“A COMPARATIVE EVALUATION OF SERUM HEPCIDIN AND 
INTERLEUKIN-6 LEVELS BEFORE AND AFTER PHASE I PERIODONTAL 
THERAPY IN PATIENTS WITH CHRONIC AND AGGRESSIVE 
PERIODONTITIS” 
 “I have read the foregoing information, or it has been read to me. I have had 
the opportunity to ask questions about it and any questions I have asked have been 
answered to my satisfaction. I consent voluntarily to participate as a participant in this 
study and understand that I have the right to withdraw from the study at any time 
without in any way it affecting my further medical care.” 
 
 ________________        __________________________         _______________ 
           Date                     Name of the participant          Signature/Thumb impression 
         Of the participant 
 
[The literate witness selected by the participant must sign the informed consent form. 
The witness should not have any relationship with the research team; If the participant 
does not want to disclose his/her participation details to others, in view of respecting 
the wishes of the participant, he/she can be allowed to waive from the witness 
procedure. (This is applicable to literate participant ONLY). This should be 
documented by the study staff by getting signature from the prospective participant.] 
 
“I have witnessed the accurate reading of the consent form to the potential 
participant and the individual has had opportunity to ask questions. I confirm that the 
individual has given consent freely.” 
 
________________        __________________________        __________________ 
           Date   Name of the witness    Signature of the witness 
 
________________        __________________________          _________________ 
 
          Date           Name of the interviewer         Signature of the interviewer 
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Annexure 4 
 
ஆராய்சச்ி ஒப்புதல்படிவம் 
 
ஆராய்சச்ி தலைப்பு: 
“நாட்பட்ட ஈறுஅழற்சிநநாய் மற்றும் தீவிர ஈறுஅழற்சிநநாய் 
உள்ளவரக்ளின் இரத்தத்தில் ஹப்சிடின் மற்றும் இன்டரல்ூகின்-6 அளவவ 
அறுவவசிகிசவ்சயில்லா ஈறுமருத்துவதத்ிற்கு முன்பும் பின்பும் ஒப்பிடட்ு 
மதிப்பீடு சசய்தல்" 
 
சபயர:்       வயது/பால்: 
முகவரி:                    சதாவலநபசி: 
புறநநாயாளிஎண்: 
ஆராய்சச்ிநசரக்்வகஎண்: 
 
நான் _______________________________  வயது __________ என்னுவடய 
சுயநிவனவுடனுன் மற்றும் முழு சுதந்திரதத்ிரத்துடனும் இந்த மருதத்ுவ 
ஆராய்சச்ியில் என்வன நசரத்்துக்சகாள்ள ஒப்புதல் அளிக்கிநறன். 
 
கீழ்காணப்படும் நிபந்தவனகளுக்கு நான் சம்மதிக்கிநறன்: 
நான் இந்த ஆராய்சச்ியின் நநாக்கம் மற்றும் சசய்முவறகள் பற்றி 
முழுவமயாக சதரிவிக்கப்பட்டுள்நளன். 
என் உடல்நலம் பாதிக்கப்பட்டாநலா அல்லது எதிரப்ாராத 
வழகத்திற்குமாறான நநாய்குறிகள் சதன்பட்டாநளா அதற்கு சிகிசவ்ச 
சபற்று சகாள்வதற்கும் முழு உரிவம உள்ளதாக அறிகிநறன். 
நான் எற்கனநவ உடச்காண்ட மற்றம் உடச்காள்கின்ற மருந்துகளின் 
விபரங்கவள ஆராய்சியாளரிடம் சதரிவித்துள்நளன். 
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என் மருதத்ுவகுறிப்நபடுகவள இந்தஆராய்சச்ியிள் 
பயன்படுத்திக்சகாள்ள சம்மதிக்கிநறன். 
இந்ந ஆராய்சச்ி வமயமும் ஆராய்சச்ியாளரும் என்னுவடய விபரங்கள் 
அவனதத்யும் இரகசியமாகவவப்பதாக அறிகிநறன். 
 
 
_______________________________         __________________           ______ 
    நநாயாளியின்சபயர ்            வகசயாப்பம்   நததி 
_______________________________  _____________________                   _________ 
   ஆராய்சச்ியாளரின்சபயர ்               வகசயாப்பம்              நததி 
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Annexure 5 
 
DEPARTMENT OF PERIODONTICS 
TAMILNADU GOVERNMENT DENTAL COLLEGE AND HOSPITAL 
CHENNAI – 600 003 
“A COMPARATIVE EVALUATION OF SERUM HEPCIDIN AND 
INTERLEUKIN-6 LEVELS BEFORE AND AFTER PHASE I PERIODONTAL 
THERAPY IN PATIENTS WITH CHRONIC AND AGGRESSIVE 
PERIODONTITIS” 
PROFORMA 
OP No:     DATE:   GROUP: 
 
NAME:     PATIENT ID No:    
 
AGE/SEX: 
 
ADDRESS:      
 
MOBILE No: 
 
OCCUPATION:     
INCOME: 
 
CHIEF COMPLAINT: 
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HISTORY OF PERSENTING ILLNESS: 
 
 
 
PAST MEDICAL HISTORY: 
 
 
PAST DENTAL HISTORY: 
 
 
HISTORY OF HABITS: 
 
 
INTRA ORAL EXAMINATION: 
1) No. of teeth present: 
 
2) Gingival Examination: 
 Colour: 
 Contour: 
 Consistency: 
 Texture: 
 Position: 
 Pigmentation: 
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3) Recession: 
4) Mobility: 
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INVESTIGATIONS 
1) Blood investigation 
 Hemoglobin count 
 Total leucocyte count 
 Differential leucocyte count 
 Bleeding time 
 Clotting time 
 Random blood sugar 
 
2) Serum Hepcidin and Interleukin-6 levels 
SAMPLE BASELINE 3 MONTHS 
HEPCIDIN 
  
INTERLEUKIN-6 
  
 
 
DIAGNOSIS 
 
 
 
 
PROGNOSIS 
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TREATMENT 
PHASE-I: 
 
 
 
 
S.NO CALCULATIONS BASELINE 3 MONTHS 
1 Plaque index   
2 Gingival bleeding index   
3 Probing pocket depth   
4 Clinical attachment level   
5 Hepcidin   
6 Interleukin-6   
 
 
 
 
SIGNATURE OF PG STUDENT    SIGNATURE OF GUIDE 
 
 
DATE 
